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Background: Tuberculosis (TB) remains the leading cause of mortality amongst people infected with 
Human Immunodeficiency Virus (HIV). Additionally, TB recurrence after successful treatment 
completion occurs more frequently amongst HIV positive people. Isoniazid provided as part of 
isoniazid preventive therapy (IPT) has been the gold standard of TB preventive therapy provision for 
the last few decades. IPT has been recommended by the World Health Organisation (WHO) and 
implemented by national health programmes in countries across the world. Despite global efforts and 
campaigns to promote IPT, uptake still remains a challenge and, progress in the operational scale- up 
of IPT is slow. Both international and in-country guidelines have advanced to recommending the use 
of IPT in HIV infected patients who have previously been treated for TB because these patients 
remain at risk for recurrent TB especially in TB endemic settings. However, there still remains a 
paucity in data on the successful programmatic use of IPT secondary to previous cured TB among 
HIV infected patients and is the focus of the current analysis from a pharmacists’ perspective.  
 
Methods: A retrospective secondary analysis was conducted from October 2009 to October 2013, 
amongst HIV infected patients, previously treated for TB, accessing HIV care at the urban CAPRISA 
clinical research clinic in Durban, South Africa. The aim of the study was to evaluate the 
implementation of Isoniazid Preventive Therapy (IPT) within the parent study titled “TB recurrence 
upon treatment with HAART” (TRuTH). Data was collected on IPT uptake, course completion, drug 
toxicity, treatment interruption, and the occurrence of incident TB either during treatment or post IPT 
completion. The multidisciplinary team approach in providing IPT to at risk HIV infected patients, 
including the specific role of the pharmacist, was also assessed. 
 
Results: There were 402 patients enrolled in the parent study. Of these 344 (85.6%) were eligible to 
receive IPT and of whom 212 (61.6%) initiated IPT. Among those that commenced IPT, 184 (86.8%) 
completed the six-month course, 24 (11.3%) permanently discontinued IPT and of these, 3.8% 
discontinued due to side effects. More women (n=130; 61.3%) were initiated on IPT (p=0.001) than 
men. Overall median adherence to IPT was 97.6% (IQR: 94.2 - 99.4). There were 22 cases of incident 
TB in this cohort: 13 occurred prior to IPT and nine after IPT (incidence rate ratio 0.67; 95% CI 0.29-
1.58; p=0.362).  
 
CONCLUSIONS: Overall, we demonstrated a successful IPT roll-out in a high TB endemic setting 
with good uptake of IPT, minimal course interruptions or side effects reported. IPT is a safe and 




ART with previous TB treatment experience. The pharmacist played an important role in continuum 
of care in IPT provision within an ART programme. This role included ensuring stable supply chain 






STRUCTURE OF THE DISSERTATION 
 
The structure of this Master’s thesis is based on guidelines provided by the College of Health 
Sciences, University of KwaZulu-Natal titled: Guidelines for Presentation of Masters and PHD 
Dissertations/Theses by Research, August 2015 version. The reference list for references cited in 
chapters 1, 2 and 4 are provided in this thesis after Chapter 4. The chapters are divided as follows: 
Chapter 1, introduces the current scale of the HIV and TB co-infection epidemic, importance of 
isoniazid preventive therapy (IPT), challenges with IPT implementation, the global and local impact 
of TB and HIV epidemics, IPT provision and uptake data, the need for HIV and TB service 
integration and barriers associated with this. A review of the IPT literature covers data from 
systematic reviews and randomised control trials, IPT uptake, IPT implementation, adherence to IPT, 
IPT related adverse effects and INH resistance. The hypothesis, aims and objectives are presented 
thereafter. Chapter 1 ends with a conceptual framework of factors associated with IPT use. 
The methodology used in the study is outlined in Chapter 2. This study is a secondary analysis of IPT 
programme roll out data amongst clinical trial participants. The study design, location and study 
population is described here. The steps involved in the implementation and the provision of IPT are 
discussed and illustrated. Finally, data collection methods, data analysis and the variables used for 
analysis are presented. 
Chapter 3 contains the published manuscript titled: “Implementing Isoniazid Preventive Therapy 
in a tuberculosis treatment-experienced cohort on ART”. It was originally submitted to the 
International Journal of Tuberculosis and Lung disease on 16 Oct 16 and revision 1 of the manuscript 
was re-submitted on 26 November 2016. The article was accepted for publication on 6 January 2017. 
All communication with the journal can be found in appendix C. Chapter 3 also describes the findings 
of the Master’s candidate’s secondary analysis of IPT implementation and treatment outcomes, a 
summary of the candidate’s and other co-authors contribution to the manuscript as well as references 
cited within the manuscript.  
Chapter 4 provides an overall discussion of the major findings from the study and how the aims and 
objectives of the study were met. The discussion also compares and contrasts the relevance of the 
findings with currently published evidence, in addition to presenting the role of the pharmacist in IPT 
implementation and provision. Study limitations are highlighted and recommendations for clinical 
practice and future research are also put forward. The concluding statements summarise the findings 
and how they support integration of current practices in the field of HIV and TB services. 
The appendices contain ethics committee approval for the study, communication with the journal 




ART dispensing, data collection documents and tools, as well as other supporting documents relevant 















1. CHAPTER ONE: INTRODUCTION 
 
1.1 Background: Scale of the problem  
 
Human immunodeficiency virus (HIV) is the one of the strongest risk factors for developing 
Tuberculosis (TB) in those with latent tuberculosis infection (LTBI), which occurs when an individual 
is infected with mycobacterium tuberculosis but does not have active TB disease (1, 2). The risk of 
developing TB in the 37 million people living with HIV globally is between 16 -27 times higher than 
the risk in the rest of the world’s population (1). In terms of the burden of disease, 10% of all incident 
TB cases were among people living with HIV and, of these 74% are from African countries (1, 3). The 
proportion of TB cases who are co-infected with HIV may exceed 50% in parts of southern Africa. The 
latest World Health Organisation (WHO) report indicates that TB remains the leading cause of mortality 
amongst people infected with HIV (1). Of the 1.7 million deaths due to TB, approximately 0.4 million 
deaths occurred amongst HIV infected people in 2016 (1, 4). 
 
Moreover, the rates of TB recurrence after treatment completion have also been shown to be higher in 
HIV positive people compared to HIV negative people (5-7). Among HIV negative individuals there is 
a 5 – 10% lifetime risk of LTBI progressing to active disease within the first five years of TB exposure 
(2). For people living with HIV their annual risk for TB acquisition is between 5-10% and progression 
from LTBI to active TB  is most likely to occur 12-18 months after infection (2, 8). In a country like 
South Africa (SA), defined by WHO for the period 2016–2020 as one of 14 countries that carry a triple 
threat of a high TB burden, a high dual TB/HIV burden and a high MDR TB burden (1) targeted TB 
and HIV prevention strategies are therefore critical public health interventions to reduce the morbidity 
and mortality associated with TB infection. 
 
TB preventive therapy is defined as the provision of one or more anti-TB drugs for LTBI in HIV positive 
individuals in order to prevent progression to active disease (9, 10). LTBI can be diagnosed using a 
tuberculin skin test (TST) or interferon-gamma release assay (IGRA) (9). Interventions include the 
provision of antiretroviral therapy (ART), co-trimoxazole therapy (CPT) provision and the roll-out of 
the Three I’s for HIV/TB management: intensified case-finding of TB (ICF), isoniazid preventive 
therapy (IPT) and infection control for TB (11, 12). ICF and initiation of anti-TB treatment decreases 
the infectiousness of TB cases and reduces the risk of subsequent disease transmission and associated 
morbidity and mortality (12). Routine screening for active TB provides the opportunity to offer 
prophylaxis, such as IPT, to those who do not have signs and symptoms of TB. As part of IPT, treatment 
of TST positive HIV-infected patients with isoniazid (INH), reduces their lifetime risk of active TB to 





INH was first discovered in 1912 and introduced for TB treatment in 1952 as one of the first drugs to 
treat TB effectively (13). INH remains one of the most potent TB drugs after more than 60 years of use 
and is relatively cheap to use for both treatment and prevention (13, 14). Although INH-resistant TB 
remains a challenge, high dose INH is still being used effectively to treat multi-drug resistant (MDR) 
TB cases (15). IPT has been the gold standard of TB preventive therapy for decades due to its known 
tolerance, potency and cost effectiveness and has established its place as a standard drug for TB 
prevention in resource-limited settings (12). More recently, the United States Food and Drug 
Administration (FDA) has approved the use of other drug regimens such as rifapentine (RPT) in 
combination with INH as TB preventive therapy, while other drug regimens testing different 
combinations, different dosing strategies and shorter courses are currently being investigated in clinical 
trials of both HIV infected and uninfected people (9).  
 
Implementation of TB preventive therapy is improving globally, however not all people eligible for IPT 
are able to access prevention according to the 2017 Global TB report (1). Based on data from 60 
countries, a total of 940 269 people who were newly enrolled in HIV care were started on TB preventive 
treatment in 2016. South Africa accounted for the largest share of the total (41%), followed by 
Mozambique, Zimbabwe and Malawi. Furthermore, of the 751 620 people newly initiated on HIV care 
in SA in 2016 approximately 385 932 are on IPT placing IPT coverage at 51% (1, 16). Promotion of 
IPT by healthcare workers (HCWs) and uptake of IPT by patients has been impeded by several factors. 
These include the lack of a standardised approach to exclude active TB disease, the fear of promoting 
INH resistance, additional pill burden, potential for additive side effects and the need for monthly clinic 
visits to assess for TB symptoms (17-19). Concerns regarding the optimal duration of treatment and the 
durability of the protective effect after IPT is stopped may be included as barriers to IPT scale-up (20). 
  
1.2 Context for the study: The importance of IPT implementation 
 
The integration of HIV and TB prevention care and treatment services to reduce morbidity and mortality 
caused by TB disease in people living with HIV is recommended to promote both convenient uptake of 
treatments by patients and to reduce complexity in providing treatment by HCWs (21). Best practices 
and models that have been used to integrate delivery of TB and HIV medication can be used to deliver 
IPT (22, 23). In Figure 1, a fully integrated service is proposed whereby a combined package of HIV 
and TB care is offered by healthcare personnel who are cross trained to provide screening, treatment 











Figure 1: Integrated TB and HIV service delivery adapted from various models (22, 23) 
 
As an important public health intervention for preventing the progression of LTBI to active TB disease 
among people living with HIV (24-26) IPT provision has been included in the WHO Stop TB and the 
new End TB strategy (27). Key WHO recommendations for TB strategies (Figure 2) have evolved as 
follows (27): 
Clinic A:















TB and HIV fully 
integrated and co-
located service: ART 





Clinic C: Partial integration under 
one roof with separate HIV and TB 
services: 
HIV testing, CPT, 
ART, IPT 
TB diagnosis, TB 





Figure 2: Progression of WHO global TB strategies (27) 
• The Directly Observed Therapy (DOTS) strategy focused on government commitment, passive 
case finding, standardized treatment for all confirmed sputum smear positive TB, adequate drug 
supply of all essential anti-TB drugs, as well as establishment of a monitoring and evaluation 
system 
• STOP TB strategy propagated the pursuit of high-quality DOTS; address the challenges of co-
infection (TB/HIV) as well as MDR-TB; health system strengthening; engagement of all 
healthcare providers, people with TB and communities, create, promote and enhance research 
opportunities 
• Going forward, the END TB strategy (Table 1) takes the following approach: Integrated, 
patient-centred care and prevention, bold policies and supportive systems, intensified research 














Table 1: End TB strategy 2015:WHO package of interventions for country level adaptation (27) 
END TB PILLARS AND PRINCIPLES 
PILLAR 1 PILLAR 2 PILLAR 3 
Integrated, patient-centred TB 
care and prevention 
Bold policies and supportive 
systems 
Intensified research and 
innovation 
PRINCIPLES 
Government stewardship and accountability, with monitoring and evaluation 
Strong coalition with civil society organizations and communities 
Protection and promotion of human rights, ethics and equity 
Adaptation of the strategy and targets at country level, with global collaboration 
 
The WHO has created the End TB strategy  by launching country specific responses to halt the spread 
of TB and realise the vision of “ a world free of TB” (27). The End TB strategy aims to achieve one of 
the targets of the United Nations Development programme (UNDP) Sustainable Development Goals 
(SDG), specifically SDG 3, which endeavours to see the end of the TB epidemic by 2030 (28). In the 
last 12 years, under these directives, TB-related mortality has declined by 36% amongst HIV infected 
individuals and interventions to prevent, diagnose and treat TB have saved an estimated 37 million 
people between 2000 to 2013 (28). 
The End TB package is based on 3 pillars and 4 principles (Table 1). One of the main components of 
the first pillar is preventive therapy. Based on country income, availability of resources and 
classification of TB burden, the WHO has put forward different recommendations for LTBI 
management (Table 2) which incorporates guidance on provision of IPT or other preventive regimens 






Table 2: Current WHO recommendations for LTBI (27) 
Recommendations for the management of LTBI 
COUNTRY 
GROUP 
Resource-limited and other middle-income countries with an estimated TB 
incidence rate of > 100 per 100 000 population 
High-income and upper middle-income countries with an estimated TB 





Children under 5 years of age who are household contacts of someone with TB  
Strongly recommended for the following risk groups: 
• HIV infected people 
• Adults and children who are household or close contacts of pulmonary 
TB cases 
• Clinical indications - patients with silicosis; patients initiating anti-




Investigate to exclude active TB. A LTBI test is not required prior to LTBI 
treatment, but is encouraged for those that are HIV infected. 
IGRA should not replace TST. A positive test, either a TST or IGRA test is 





6 months daily INH 
6 months daily INH 
9 months daily INH 
3 months weekly rifapentine plus INH 
3 to 4 months daily INH plus rifampicin 
3 to 4 months daily rifampicin 
Key: IGRA= interferon gamma release assay; TST= tuberculin skin test 
 
The impact of IPT on improving TB-related mortality and morbidity in HIV infected patients has been 
investigated (29-31). Although ART lowers the risk of TB due to restoration of immunity, preventive 
therapy with INH further reduces the incidence of TB compared to ART alone (32). The TEMPRANO 
study demonstrated six months of IPT combined with early ART resulted in a 44% reduction in risk of 
severe HIV related illness and reduced all-cause mortality by 35% (31). IPT was shown to decrease 




whilst in a study amongst South Africans on ART initiating IPT reported 49% reduction in mortality 
that remained significant even for those that had a past history of TB (29). Other trials have shown that 
overall maximum benefits from TB preventive therapy are achieved in HIV-infected persons with a 
positive TST (30, 33) and that TST positive patients were shown to benefit the most by completing a 
36 month IPT course, resulting in a 74% decreased active TB risk and 68% decrease in mortality when 
compared to 6 months of IPT (34). However, benefit has also been shown among HIV-infected persons 
in general, regardless of their tuberculin test result (35). The Thibela study, which was conducted among 
mineworkers in whom HIV prevalence was not established, demonstrated a 58% reduction in TB 
infection during a 9 month course of IPT (36, 37). However, the protective effect diminished rapidly 
after IPT course completion. The authors suggest that this could possibly be due to reactivation of 
inadequately treated LTBI or reinfection caused by high rates of ongoing transmission in this group. 
(37). 
 
After the earlier policy in 1998, the WHO released updated IPT guidelines in 2011 (Figure 3) and 
recommended the use of 36 months IPT for the HIV infected and TST positive individuals in high TB-
prevalence and transmission settings, based on the results of unpublished studies (12). In 2015, the 
evidence was re-assessed and the conditional recommendation retained (38). This was significant for 
adults, adolescent, pregnant women and children living with HIV and those who have successfully 
completed TB treatment, on ART in settings with high TB and HIV prevalence and transmission.  
 
The first South African (SA) guidelines for IPT were released in 2004 (39), revised in 2010 (10) and 
again in 2013 as part of the national ART guidelines (40) and subsequently as part of the 2015 national 
consolidated guidelines (41) (Figure 3). In 2004, the guidance excluded patients with any previous TB 
episode within the last 2 years, those who had started ART were not offered IPT as there was no 
evidence of benefit and IPT was not offered to TST negative patients (39). IPT could only be offered 
once and the protective effect was expected to last 18 months (39). With the evidence-based updates to 
the guidelines and in keeping with WHO recommendations (Table 3) HIV infected people on ART in 
SA are to be offered 12 months of IPT if they are TST negative and at least 36 months if they are TST 
positive (40, 41). TB preventive therapy is now seen as an intervention that should be part of the package 
of care for the HIV infected people and should be rolled out at all public health services. TB preventive 
therapy should only be offered under the following conditions: patients are screened for active TB 
disease before initiation of IPT; providers must follow up and monitor patients to encourage adherence, 
address side-effects and exclude active TB disease (41). 
 
The criteria for non-eligibility to IPT has also been defined in the current South African guidelines (41):  




• active liver disease (acute or chronic)  
• peripheral neuropathy  
• history of adverse reaction to INH  
• HIV positive but TST negative in pre-ART care  
• excessive alcohol use: more than 28 units per week for men and 21 units per week for women  
• previous multidrug-resistant (MDR) or Extensively drug-resistant (XDR) TB  









Table 3: Current SA IPT eligibility criteria (41) 
POPULATION DURATION OF IPT COMMENT 
Pregnant/breastfeeding HIV positive women TST positive: 36 months 
TST negative: 12 months 
TST not available: 12 months 
Lifelong ART preferred. Start IPT at any time during 
pregnancy/breastfeeding, first then add IPT after 1 month. If pregnant 
while on IPT, continue IPT. If TST negative, re-assess TST status 1 
year after completing IPT. 
Children <5years old with recent exposure to TB 
contact regardless of HIV status 
6 months Recent refers to <12 months. If re-exposed to a TB case after 
completion of 6 months IPT, repeat another course of IPT irrespective 
of interval between treatment and re-exposure. If child is exposed to 
new infectious source while on IPT, continue IPT for as long as source 
remains infectious. 
All HIV-positive children up to 15years old with 
recent exposure to TB case 
Pre-ART patients regardless of CD4 
(Adolescent/Adult) 
TST positive: 36 months; TST negative: No IPT; TST 
not available: 6 months; If later TST becomes negative: 
stop IPT. If later TST becomes positive: extend to 36 
months. 
Only TST positive get IPT regardless of CD4. If TST negative, re-
assess TST status annually in Pre-ART. IPT can be started anytime. If 
patient becomes eligible for ART while on IPT, initiate ART and 
continue IPT. If eligible for both ART and IPT, start with ART, 
followed by IPT when stable on ART. 
Patients on ART (Adolescent/adult) TST positive: 36 months; TST negative: 12 months; 
TST not available: 12 months. If later TST becomes 
positive: extend IPT to 36 months. 
All eligible for IPT regardless of CD4 count. If TST negative, re-assess 
TST status and IPT eligibility 1 year after completing IPT. 
Former TB adult patients (Excluding MDR/XDR 
and children) 
TST positive: 36 months; TST negative: 12 months 
TST not available: 12 months; If later TST becomes 
positive: extend IPT to 36 months. 
There must be documented proof of bacteriological cure. If there is no 
proof of cure, do not give IPT, re-assess for IPT eligibility after 3 





1.3 Literature Review 
 
An extensive literature search on IPT, was conducted from 1980 to the current year 2016, using the 
following databases: PubMed, Google scholar and WorldCat. Key words and search strings included 
the following medical subject headings (MeSH): "isoniazid"[MeSH Terms] OR "isoniazid"[All 
Fields]) AND ("prevention and control"[Subheading] OR ("prevention"[All Fields] AND 
"control"[All Fields]) OR "prevention and control"[All Fields] OR ("preventive"[All Fields] AND 
"therapy"[All Fields]) OR "preventive therapy"[All Fields]) AND IPT[All Fields] AND TB[All 
Fields] AND ("prevention and control"[Subheading] OR ("prevention"[All Fields] AND "control"[All 
Fields]) OR "prevention and control"[All Fields] OR ("preventive"[All Fields] AND "therapy"[All 
Fields]) OR "preventive therapy"[All Fields]) AND TB[All Fields] AND ("prevention and 
control"[Subheading] OR ("prevention"[All Fields] AND "control"[All Fields]) OR "prevention and 
control"[All Fields] OR "prevention"[All Fields]). Research has focused on IPT use amongst special 
populations: HIV infected people, prisoners, mine workers, paediatrics and pregnant women. While 
mine workers are an at-risk population significant within the South African context and setting, the 
other special populations listed above were excluded from this literature review.  
Systematic reviews 
A Cochrane Review conducted in 2004 (43) included 8130 participants in 11 trials that demonstrated 
efficacy of IPT in HIV+ adults with an overall 32% reduction in TB. In 2010, another systematic review 
aimed at updating the previous review was conducted and also confirmed the above findings (44) after 
looking at 12 trials with 8578 participants. It was noted that the trials reviewed did not determine if HIV 
infected patients in high TB burden areas should get repeated courses or lifelong IPT, nor did they 
provide data on adherence, INH The first South African (SA) guidelines for IPT were released in 2004 
(39), revised in 2010 (10) and again in 2013 as part of the national ART guidelines (40) and 
subsequently as part of the 2015 national consolidated guidelines (41) (Figure 3). In 2004, the guidance 
excluded patients with any previous TB episode within the last 2 years, those who had started ART 
were not offered IPT as there was no evidence of benefit and IPT was not offered to TST negative 
patients (39). IPT could only be offered once and the protective effect was expected to last 18 months 
(39). With the evidence-based updates to the guidelines and in keeping with WHO recommendations 
(Table 3) HIV infected people on ART in SA are to be offered 12 months of IPT if they are TST negative 
and at least 36 months if they are TST positive (40, 41). TB preventive therapy is now seen as an 
intervention that should be part of the package of care for the HIV infected people and should be rolled 
out at all public health services. TB preventive therapy should only be offered under the following 
conditions: patients are screened for active TB disease before initiation of IPT; providers must follow 
up and monitor patients to encourage adherence, address side-effects and exclude active TB disease 




This review also highlighted the need for clinical trial evaluations of the effectiveness of combined 
ART and TB preventive therapy. 
 
In 2011 a systematic review on the integration of HIV and TB services amongst sub-Saharan African 
(SSA) countries (45) described the extent to which integration has occurred at various facility levels 
and what the overall impact was. This review looked at 56 articles (total number of participants not 
reported) and those findings specific to IPT and ART provision are highlighted here. Of the 81-93% of 
HIV positive people screened for IPT, 13- 95% were eventually initiated on IPT. Adherence to IPT was 
in the range of 75-92% and 6 month IPT completion rates were reported be between 47 – 88%. Some 
studies reported high IPT lost-to-follow-up rates. The prevalence of HIV was 9 - 85% and uptake of 
ART was ≤ 41%. This review confirmed the results of the Cochrane review that IPT did decrease the 
risk of all-cause mortality. IPT was found to be cost effective in comparison to secondary TB cases 
prevented. The review also reported that IPT reduced TB incidence risk by 62% in TST positive HIV 
infected individuals (relative risk: 0.38, 95% CI: 0.25 – 0.57) over those that received ART only or no 
treatment at all. 
 
More recently a systematic review conducted by Ayele et al. in 2015, analysed IPT outcomes in 
comparison to placebo or no treatment in 7619 HIV positive populations from ten randomised control 
trials (46). Their main findings indicated that overall TB risk was reduced by 35% [RR = 0.65, 95%CI 
(0.51, 0.84)]. Similar to other reviews, those participants with a positive Tuberculin Skin Test (TST) 
achieved the most benefit [RR = 0.48; 95% CI (0.29 -0.82)]. A reduced risk of HIV disease progression 
was seen in all participants [RR = 0.69; 95% CI (0.48 - 0.99)]. IPT did not impact on all-cause mortality; 
however, 12 months IPT duration reduced risk [RR = 0.65; 95% CI (0.47- 0.90)]. IPT-related drug 
toxicity risk was not significant [RR = 1.20; 95% CI (1.20, 1.71)].  
 
Specifically relevant to secondary preventive therapy (sPT) in patients previously treated for TB, a 
systematic review was conducted by Bruins and van Leth (47) that reviewed 4 articles and 1204 
participants.  They reported a beneficial effect of sPT in reducing TB incidence ranging from 55.0% to 
82.1% (RR: 0.18–0.45). Their findings highlighted the following: the optimum duration of preventive 
therapy remains unknown, the ideal drug regimen/s that should be used is still under debate. sPT use 
varied from 6 months till 2 years and some drug regimens used included Rifampicin together with INH. 
The authors also suggested further studies be conducted to assess the impact of combined ART use with 
sPT as well as drug resistance.  
 
Randomised Clinical Trials 





BOTUSA Study (34, 48): This study was conducted in Botswana among a total of 1995 black adult 
miners ≥ 18 years. Only 2% were on ART at enrolment. Forty-five percent started ART at a median of 
4 months after enrolment. The cohort comprised of 71% females; the CD4 median was 307 cell/mm3 
(176-457 cell/mm3), mean CD4 was 220 cell/mm3 and median age was 32. Patients were randomised 
to receive 6 months or 36 months IPT. Tuberculin skin tests (TST) were conducted at screening. 
Incident TB was the primary endpoint, with death being the secondary endpoint. It was found that the 
IPT protective effect, after a 6-month course, was lost after approximately 200 days. INH resistance 
was reported as 18% and similar to the known background resistance. Mortality was 1.3% per year. 
Mortality rates were the same between study groups, but for participants with a positive tuberculin skin 
test mortality was 3 times lower in the long term IPT group. It was found that a 36-month course resulted 
in a 43% reduction in incident TB and 74% amongst those who had a positive TST. The use of ART 
was found to be additive to the protective effect of IPT and did not escalate rates of INH induced 
hepatitis amongst the cohort. Severe side effects were similar in both arms: 1.4% in the 6-month group 
and 1.6% in the 36-month group. Study limitations included the following: only 61% of the TB cases 
in the study were culture positive; ART use was not controlled in the study but rather it was observed; 
findings may not be generalizable as screening procedures included more laboratory tests and chest 
radiographs not normally required as part of standard of care at the time.  
 
Thibela Study (36, 37, 49): In the intervention arm of the Thibela Study, active TB screening was used 
to identify eligible patients and in turn offer them IPT. There was a massive scale-up of IPT provided 
as a 9 month course among miners in South Africa where 23585 patients started INH from July 06 – 31 
Mar 09. In this study, there was a 58% reduction in TB incidence during treatment. However, the 
protective effect did not last long after treatment was stopped. The authors did report what the duration 
of the protective effect of IPT was in this study. The eventual overall outcome was that there was no 
difference between the intervention and control arms in terms of TB prevalence (2.35 % vs 2.14%) or 
incidence (3.02 vs 2.95 cases per 100 person years). Twenty-six adverse events were recorded: 60 
hypersensitivity; 49 peripheral neuropathy; 14 hepatitis; 3 convulsions; 4 serious adverse events 
(SAEs): 3 hepatitis; 1 definitely related; 1 convulsion; possibly related. There were 33 deaths: 31 not 
related; 1 possibly related; 1 relationship to INH not coded. There was no evidence of increased INH 
resistance. The investigators highlighted that for community wide intervention to succeed and TB 
transmission to be interrupted, there would have to be faster IPT implementation, greater uptake and 
retention within a programme, in conjunction with ART provision as well as rapid TB case detection 
and treatment initiation. One of the limitations reported in the study included being unable to determine 





ThRio study (32): was conducted in Brazil to look at TB incidence among 11 026 HIV-infected patients 
in 29 public clinics in Rio de Janeiro, between September 2003 to September 2005. The cohort was 
from 16 – 84 years of age, 38.1% were females and more than 50% had CD4 > 200 cells/mm3, with 
73% on ART and 9.9 % on IPT at baseline. Results obtained as follows: 67 TB incident cases [IRR 
2.28/100 person years; 95% CI 2.06 – 2.52]; without IPT or HAART, IR 4.01; HAART alone, IR 1.90 
(95% CI 1.66 – 2.17); IPT alone, IR 1.27 (95% CI 0.41–2.95); HAART after IPT, IR 0.80 (95% CI 
0.38–1.47). It was found that compared to treatment-naive patients, patients receiving HAART after 
IPT had a 76% reduced TB risk. Limitations reported by the study included: missing data due to the 
retrospective nature of study; no standardised method of clinical monitoring; reasons for eligibility or 
non-eligibility for TST; ART and IPT usage was known for some patients but not in others. Also that 
low IPT uptake could have impacted on TB incidence estimates.  
 
TEMPRANO study (31): was designed to assess 4 different treatment approaches: immediate ART, 6 
months of IPT, a combination of immediate ART plus 6 months IPT or deferred ART (until WHO 
defined criteria were met for initiation). Approximately 2056 adults ≥18 years were randomised to either 
early or deferred groups for ART and IPT, with > 75% females, median age 35, with CD4 =459 
cells/mm3 (deferred) and 466 cells/mm3 (early). ART use was 71% in the deferred and 68% in the early 
group. Early ART effect seen at month 12 was 84% where viral loads were undetectable and at month 
24 83% were undetectable. Overall, CD4+ T-cell count remained above 500 cells/mm3 for 51% of the 
time. The cumulative probability of death or severe HIV-related illness in the early group was 5.7% and 
deferred group was 8.8%. The outcome of early ART and IPT initiation was 44% reduction of severe 
HIV-related illness and 35 % decrease in all-cause mortality (Table 4) when compared to the deferred 
group. Previous recommendations for early ART initiation were based on observational data; the 
landmark TEMPRANO study confirmed these findings. However, one of the limitations reported by 
the authors was that it could not be determined if ART should be started at higher CD4 levels or initiated 
in all HIV infected participants irrespective of the CD4 count. In a follow up study on the post-trial 
phase of TEMPRANO (50), the protective effect of IPT on mortality was demonstrated even in people 
with high CD4 counts on ART, with a 37% reduction in mortality that appeared to be sustainable for 
up to 6 years. 
 
IPT effect on mortality 
Studies conducted in the pre-ART era did not conclusively demonstrate that IPT reduced TB related 
deaths. In contrast to these pre-ART studies, findings from studies conducted in patients on ART and 
IPT did demonstrate an effect in decreasing mortality. An earlier study conducted in Haiti in 2000 
(Table 4) amongst a mixed cohort HIV negative and positive people on IPT showed no effect on TB 




Another 2001 Zambian study in HIV infected people not on ART used different preventive therapy 
regimens and found none of the regimens had any effect on mortality (52). Patients in Tanzania (30) 
had a 60% decrease in mortality if they completed IPT successfully. In a study done by Charalambous 
et al. those South Africans on ART that received IPT experienced significant mortality reduction of 
48% if they had a past history of TB and 56% if no prior TB history, when compared to no IPT (7). A 
2015 study in Ethiopia (53) demonstrated that the combined effect of ART and IPT reduced mortality 
by 60%. The major clinical trials like BOTUSA and TEMPRANO also reported statistically significant 
reductions in mortality in patients on ART and IPT (Table 4). 
 
IPT protective effect duration 
There have been inconsistent results reported on the duration of the protective effect offered by IPT 
amongst users (36, 46, 54-56)  which limits implementation of IPT and minimises the potential benefits 
of IPT especially in high TB/HIV burden areas that are in most dire need of it. While in some high 
burden settings TB risk among IPT users escalated as soon as treatment was stopped, those that 
completed longer IPT courses had better long term outcomes (34, 36, 57). A subsequent study on the 
protective effect post IPT completion in the same cohort in Haiti discussed above revealed that the 
longer the duration of the IPT course the greater the length of time to TB incidence (Table 4), thereby 
prolonging the protection offered by IPT (58). The BOTUSA study demonstrated that the IPT protective 
effect lasted 200 days after 6 months IPT was completed (34). Post-trial data showed that TB cases 
occurred most frequently within the first year after IPT irrespective of whether the patient received 6 or 
36 months IPT (57). A Zambian study demonstrated a protective effect for 2.5 years of follow up, but 
with steady decline in the effect occurring after the first 1.5 years (52). In Thailand, IPT benefit was 
significant for the first 6 months after completion before declining; with no difference in TB incidence 
between those that took IPT and those that didn’t, at 4 years post IPT (59). In Uganda, the benefit of 6 
months IPT was lost within one year and 3 months PT with INH plus rifampicin or pyrazinamide lasted 




Mills et al. looked into modelling the effects of community-wide IPT implementation on TB incidence 
as well as to determine what differences may occur at population and individual level within high 
burden settings as a result (61). Their model found that TB was almost eliminated in some areas but in 
others, IPT was ineffective due to continuous re-infection. According to their findings, with the scale 
up of IPT the protective effect could vary depending on the force of TB transmission in that community.  
Importantly, while INH resistance may not be impacted at individual level, community wide IPT may 




IPT was able to ‘cure’ LTBI in patients on ART and thereby able to bestow increased duration of 
protection after course completion (62). They calculated the annual risk of infection to be 4.0% (2.6–
5.8) and they estimated 35.4% (2.4-76.4) or one third of LTBI had been cured. Their model suggested 
that 12 months IPT may provide additional long-term benefit in patients on ART in low burden settings 
only and re-infection in high burden settings would limit the protective effect of IPT. Overall, it must 
be noted that the very assumptions made in order to construct various statistical models serve as 
limitations as they influence the final results or predictions obtained from these models. Models may 
suggest a trend or direct effect that may be over-, under- or incorrectly interpreted. So while modelling 
may help guide future research endeavours, it cannot confirm nor negate any clinical outcomes with 
complete accuracy.  
 
Some models from studies conducted in settings like Brazil showed that combined IPT and ART 
delivery could result in reduction of TB incidence and mortality (55, 63, 64). Researchers in Brazil 
developed a transmission model using IPT implementation data among patient on ART in the THRio 
study. The model demonstrated IPT coverage at 20% of 2500 eligible patients every year and after 5 
years, IPT had reduced general population TB incidence by 3.0% and in HIV infected by 15.6%; with 
TB mortality reduced by 4.0% and 14.3% respectively. A group of South African researchers took to 
modelling data from the Thibela TB study and discovered that very little of the LTBI was cured by IPT 
provision to gold miners in the study (65). Using the model to demonstrate an optimized IPT rollout 
only showed 10% increase in impact. The use of additional interventions such as reducing treatment 
delays, increased ART coverage, improved diagnostics, and continuous IPT with ART use in the model 
contributed to 30% reduction in TB incidence individually and 75% in combination, after 10 years. In 
2015, Reid et al. (66) looked at the same model above in conjunction with another South African based 
modelling strategy (67) and further emphasized the necessity of a multi-pronged approach of treatment 
and prevention to end the TB epidemic in SA (66). 
 
Effect on TB incidence 
Table 4 includes the TB incidence reported by various clinical trial and observational studies. The 
benefits of combined ART and IPT are clearly evident with the lowest TB incidence levels occurring 
in patients on ART and IPT (31, 32, 53, 54, 57, 68). Also, IPT seems to be more effective in those with 
no history of previous TB or at least 1 past TB episode compared to > 1 episode of TB in the past (29, 
69).  
 
IPT secondary to previous TB 
Only a few studies have been conducted in which the entire cohort had previous TB infection and 




Fitzgerald et al. in 2000 and Churchyard et al. in 2003. Haller et al. found that secondary IPT 
somewhat reduced mortality but noted a significant decrease in TB incidence as well as adverse 
events when compared to no IPT (70). In 2000, Fitzgerald et al. reported 72% reduction in TB 
incidence among HIV infected but no effect in HIV uninfected individuals (51). Churchyard et al. 
reported that IPT effect was strongest amongst those who had had 1 previous episode of TB 
specifically with 89% reduction compared to those that had more than one TB episode and that the 





Table 4: IPT implementation outcomes  








IPT regimen IPT outcome 
TB incidence/P100PY, IR, 
















No No 3H300, 
6H300 
12H300 or P 
P: no reduction,  
3H:21% (RR),  
6H 65% (RR1.4),  
12H 75% (RR1.0) 
 
1124 (4%) deaths 
over 5 years; 3 cases 
due to INH induced 
hepatitis where INH 
wasn’t stopped at 
first signs of 
symptoms. 3 TB 
deaths all in P arm 
(0.42 /100PY) 
Protective effect increased with 
IPT duration but efficacy of each 
regimen in comparison to placebo 
changed gradually during 5 year 
follow up. The greatest increase 
in number of TB cases prevented 
was during 12 to 24 weeks IPT. 








No Positive & 
negative 
6INH300 vs P IR: IPT = 4.29/100PY [95% 
CI: 2.7–6.33] 
P =3.86/100PY [95% CI: 
2.45–5.79] 
aRR = overall 0.92 (95% CI: 
0.49–1.71);  
TST+ 0.60 (95% CI: 0.23–
1.60)  
TST‐1.23 (95% CI: 0.55–
2.76) [p=0.26] 
 
aRR for mortality 
overall: 1.18 (95% 
CI, 0.79-1.75) 
TST (+): 0.33 (95% 
CI, 0.09-1.23)  
TST (-): 1.39  (95% 
CI, 0.90-2.12). 
70.2% completed treatment 
phase. 












IPT regimen IPT outcome 
TB incidence/P100PY, IR, 























6H300 or 6P 
Monthly visit 
for 6 months, 
then 3 
monthly 
RR compared to placebo:  
H=0.33 (0.14-0.77);  
HR= 0.40 (0.18 to 0.86);  
RZ= 0.51 (0.24-1.08) 
overall mortality rate 
was > in PPD (-) than 
in the PPD (+) 
(P=0.001) but no 
difference in survival 
observed between the 
two groups 
Year 1  
PPD (+) = 0.78 
PPD (-) = 0.90 
 (P=0.001 by the log-
rank test).  
TB cases: 20% 
mortality rate 
6H300 reduced TB by 67% with 
minimal side effects compared to 
other regimens.  Duration of 





1053 ≥ 15, Black 
African 










weekly or 6P 
twice weekly)  
IR p100PY/crude  
RR: H Arm- 2.74/0.56 vs P; 
RZ Arm- 3.16/0.65 vs P;  
P Arm- 4.94/0.6 for RZ or H 
vs P 
 
185 deaths, mortality 
increased with follow 
up time but no 




negative and Hb 
96 cases (59 TB & 37 probable) 
TB rate increased and protective 
effect decreased with time= after 
18 months i.e. 1 year post 
completion (p=0.25) 
Most effective in those with 
Lymphocyte count 2X109 /l or 
higher, TST+ and Hb ≥ 10mg/dl 
 
Africa, 1999 
Haller (70)  
263 ≥ 18, Black 
African 
 
Yes No Not known 6H300+ SP ↓ TB incidence (log rank test: 
p = 0. 0234), 
Decrease in mortality 
(log rank test: p = 
0.1736) 
reduction of adverse events and 
sick days [22 (IPT) VS 77 
(control)] prevention of wasting 













IPT regimen IPT outcome 
TB incidence/P100PY, IR, 






288 ≥ 18, ?race Yes No Negative IPT=12H300 
vs 12P, no 
DOT 
P Arm IR 7.8 (4.1-13.3)  
IPT Arm 1.4 (0.0-3.4) 
1 TB case during IPT 
 
IPT did not affect 
mortality 
 
TB regimen: 2RHZ daily 
regimen, weekly clinic visits, no 
DOT 
CP=4RH 2 X weekly regimen, 
DOT 
IPT had no effect on HIV 
negative 
82% reduction 
TB recurrence occurred in those 
with HIV symptoms 
Zambia, 2001 
Quigley (52) 










bi weekly, 3P 
and 6P  
 
IR:  
H: 3.0 /100PY,  
RZ: 3.7/100PY,  
P: 4.3/100PY 
 
Higher mortality in 
RZ than placebo 
(confounding effect). 
Median survival time 
from TB 
diagnosis=33 months. 
PT did not slow HIV 
progression or affect 
mortality. 
 
PT effect strongest on TST+ in 
the 1st 1.5 years 
TB protection for both H and RZ 
lasted 2.5 years compared to 
placebo RR: 0.54 (95% CI: 0.31-
0.95; p= 0.033) 
No difference in TB incidence in 





















Overall 55% TB reduction  
aIRR:  




IPT: 8.6/100PY;  
Control: 19.1/100PY  
 
Mortality rate ratio: 
0.70 (95% CI: 0.39–
1.24) p=0.22 
IPT effect was strongest amongst 
the men who had 1 episode of 
MTB specifically: 89% reduction 
(IRR 0.11; 95% CI: 0.04–0.27). If 
>1 TB episode: IRR= 2.47 (0.30–
20.5) 
Recurrent TBIR increased with 
decreasing CD4: (CD4 cell count 
≥500 cells/mm3: 6.9/100PY; 
200–499 cells/mm3: 8.6/100 PY; 













IPT regimen IPT outcome 
TB incidence/P100PY, IR, 






Grant (36)  
1655 ≥ 18, Black 
African 
 




Prior to clinic enrolment TB 
incidence= 11.9 p100PY. 




(so TB incidence still 
remained high) 
95 deaths (15%)- 
causes not reported 
TB incidence ↓by 38% overall 
and by 46% if had no TB history.  
TB risk associated with increasing 
age, TB history, baseline WHO 
stage 3 and 4, silicosis grade 
probable or higher 
Short follow up time may account 
for higher protective effect than 






≥ 18, mixed 
race 
Yes Yes Positive + 
negative 
6H300 IR overall: 2.28/100PY (2.03-
2.52) 
No ART or IPT: 4.01/100PY  
ART: 1.90/1000PY (1.66-
2.17) 
IPT: 1.27/100PY (0.41-2.395) 
ART + IPT: 0.8/100py (0.38-
1.47)  
76% TB risk reduction 
(P<0.001) with IPT + ART 
use 
 
Not assessed Past history of TB ↑risk of TB 
during follow up for patients with 
higher CD4 













IPT regimen IPT outcome 
TB incidence/P100PY, IR, 














No Positive 6H300 Not provided 6 deaths (8%) none 
related to IPT 
91% IPT uptake, 87% completed. 
Of the 13% Non- completion 
cohort: 4% Dr initiated, 7% 
patient and 1% death (not due to 
INH). Completers had a family 
member / friend with TB (65% 
vs.12%, 95% CI: 0.185–0.875, P 
< 0.03), think IPT was important 
(100% vs. 87%, 95% CI: 0.063–
0.197, P < 0.001), found 
counselling helpful (91% vs. 
63%, 95% CI: 0.0574–0.5086, P 
< 0.007), had family approval for 
their decision to take IPT (97% 
vs. 50%, 95% CI: 0.1411–0.6389, 
P < 0.001), clinic was close to 
their residence (72% vs. 43%, 
95% CI: 0.01–0.672, P < 0.04). 
Reasons reported for IPT 
completion: fear of TB 44%, 
understanding of the importance 
of IPT 32%, fear of TB and HIV 
complications 22% and other 2%. 
Reasons for non-completion: fear 
of INH side effects 14%, travel 
distance to the clinic 14%) and 
spouse’s advice 14%. Females 
were more likely to stop then 
males. Counselling and social 













IPT regimen IPT outcome 
TB incidence/P100PY, IR, 











Yes Yes 6H - dose not 
reported 
No IPT and no ART: IR: 
7.1/100PY; 95% CI: 6.2-8.2 
IPT then ART: 85%↓ 
(IR=1.1/100py; 
IRR=0.15; 95% CI: 0.004-
0.85) 
ART only VS No IPT and no 
ART: 35% ↓ 
IR: 4.6/100PY;  
IRR=0.65; 95% CI: 0.46-0.91 
IPT only VS treatment naïve: 
27 %↓ 
IR=5.2/100PY;  
IRR=0.73; 95% CI: 0.44-1.13 
ART VS treatment naïve: 64% 
aHR=0.36; 95% CI 0.25-0.51) 
IPT VS treatment naïve: 
aHR=0.87; 95% CI: 0.55-1.36 
IPT +ART VS treatment 
naïve: 89%  
aHR=0.11; 95% CI: 0.02-0.78 
 
Not provided Overall uptake = 13%; Urban 
cohort = 17%; Rural cohort =1%. 
Men more likely to get TB (IRR 
1.46; 95% CI: 1.09-1.94) 






1995 ≥18, Black 
African 





8 TB cases (0.4%) 
Lower TB rate attributed to 
concomitant ART 
20 deaths (1%) 
 
6H open label phase of BOTUSA 
Study 
Initially weight dependant dosing: 
300mg: 30-49 kg 
400mg: ≥ 50kg; then changed in 

















no IPT: 11.08/100PY.  
HR  






(aHR: 0.50, 95% CI: 
0.32 – 0.80) 
Those with a past history of TB 
aHR 0.52 (95%CI 0.32 – 0.82); 
those with no TB aHR 0.44 (95% 












IPT regimen IPT outcome 
TB incidence/P100PY, IR, 

















No difference on TB incidence 
between IPT completers and 
non-completers HR=0.6 (95% 
CI: 0.3-1.3; log-rank P=0.92)  
 
IPT completers had 
longer survival 
p<0.001, 60% ↓ in 
mortality, HR=0.4 
(95% CI: 0.2-0.8) 
Non-significant protective effect 
of IPT aHR=0.6 (0.3-1.3) 





















(HR 0.57; 95% CI: 0.33-0.99; 
p=0.047)  
36H=↓TB incidence by 43% 
(In TST+: 74%) 
IPT arm:  
ART+IPT=50% TB reduction 
TST + 36H VS 6H HR: 0.26 
(95% CI: 0.08-0.80, P=0.02) 
during trial; 0.33 (95% CI: 
0.16-0.68; P=0.003) trial and 
post-trial; 0.40 (95% CI: 0.15-
1.08; P= 0.07) post trial  
 
 
TST+ had 3 times 
lower rates of TB and 
mortality. Mortality: 
TST + 36H VS 6H 
HR: 0.32 (95% CI: 
0.11-0.90, P=0.0031) 
during trial; 0.41 
(95% CI: 0.18-0.91; 
P=0.028) trial and 
post-trial; 0.62 (95% 
CI: 0.17-2.32; P= 
0.48) post trial 
If CD4> 200 
cells/mm3: HR 0.26 
(0.09-0.71) p<0.05 
post-trial 
if 360 days ART VS 
no ART: HR 0.36 
(0.17-0.75) 
 
TST- had no significant IPT 
benefit but had ART benefit 
CD4>200 had more IPT benefit 
then CD4<200 













IPT regimen IPT outcome 
TB incidence/P100PY, IR, 






 Martinson (76) 
1148 ≥ 18, Black 
African 





TB IR: RPT/H- 3.1/100PY,  
RH-2.9/100PY,  
36H- 2.7/100PY,  
6H- 3.6/100PY(P>0.05 for all 
comparisons) 
66 deaths 




the 3 cohorts and the 
control group 
(P>0.05 by log-rank 
test) 
36H300 had lowest 
mortality and TB rate 
from all the groups 
 
no additional benefit of 36H300 
reported but this group had more 
discontinuations. Also post hoc 
analyses showed 36H300 
effectiveness was lost when 
treatment ended but duration of 

















not assessed Not assessed Men had higher risk of non-
adherence and LTFU (aOR: 2.24, 
95% CI: 1.24-4.04) and (aOR: 
3.08; 95% CI: 1.50-6.33) 
respectively. Self-reported 
reasons for non-adherence and 
LTFU: work commitment 
(18.9%; 19.3%), side effects 
(15.8%; 6%), thought they had 
completed study [but had not] 













IPT regimen IPT outcome 
TB incidence/P100PY, IR, 






5407 ≥ 18, Black 
African 
Not reported Yes Not done 6H300 for 
adults 
TB IR: 
No intervention: 9.1,  
IPT only: 2.4,  
IPT before ART: 2.2,  
ART only: 6.9,  
IPT & ART simultaneously: 
2.5,  
IPT after ART: 1.5 
TBIR overall:  
IPT=0.7 P100PY &  
No IPT=6.1 P100PY 
[IRR:0.11(0.08-0.15)] 
Combined effect IPT plus 
ART compared to ART only = 
TB incidence↓ by 57% 
[IRR:0.43; 0.18-0.86] 
Reported as patients 
lost to follow-up or 
dead  
IPT before ART=9% 
ART only=39% 
IPT and ART 
simultaneously=17%, 
IPT after ART= 9% 
overall among ART 
patients = 24% 
IPT effect persisted even though 
IPT completion wasn’t 
documented. First six months on 
ART was highest TB risk =8.00 
P100PY, then pre – ART= 3.9 
P100PY; risk then↓ as time on 
ART↑.  
Modelling shows that tripling the 
IPT initiation within a 2-year 
period would ↓ TB by 27% 
39% uptake of IPT=2131, 
completion only documented in 




1329 ≥ 18, Black 
African 




12H vs 12P 
Dose: 200mg 
< 50kg 
300mg ≥ 50kg 
 
TB IR:  
IPT-2.3/100PY, (95% CI: 1.6–
3.1),  
Placebo-3.6/100PY, 95% CI: 
2.8–4.7);  
HR 0.63,(95% CI 0.41–
0.94) 37% TB reduction 
with ART + IPT 
 
overall rate all-cause 
mortality= 1/100PY 
12H= 0.9/100PY  
12P= 1.2/100PY 
HR 0.72 (95% CI: 
0.34–1.34, log-rank 
p=0.32) 
37 deaths:  
TB=8 (2 INH and 6 
placebo) 
non-TB=13 unrelated 
to the study 
drug (6 INH and 7 
placebo)  
unknown reasons =16 
 
Effect was greatest in 1st year and 
then decreased over time. 
Insufficient statistical power to 
show formal interaction by time 
since randomization. 
No difference between IPT and 
Placebo arms for adverse effects, 
no additive toxicity due to 
concurrent IPT and ART. 
Contrary to other studies, both 
IGRA and TST negative patients 
benefited from IPT (aHR for 
patients with (-) tests 0·43 [0.21–
0.86] and 0.43 [0.20–0.96]; for 
(+) tests 0.86 [0.37–2.00] and 
0.55 [0.26–1.24]. Authors 
supported this finding -cited these 
may be false negative results in 
high TB burden areas especially 












IPT regimen IPT outcome 
TB incidence/P100PY, IR, 
























Post-trial period TB IR 
36H (n=851): 0.93  
6H (n=827): 1.13 
TST +: 1.3/100PY  
 
Mortality during trial 
= 1.4%; post trial-106 
deaths: 0.6(6H) & 
0.4% (36H);  
in TST+ 36H: deaths 
↓63% after IPT (HR 
0.37, p=0.088) and 
during & after trial 
↓59% (HR 0.41, 
p=0.028) 
For death post-trial - 
If CD4> 200 
cells/mm3: HR 
0.26(0.09-0.71) 
=74% and if 360 days 
ART VS no ART, 
HR 0.36 (0.17-
0.75)=64% 
98 incident TB cases- 83% DS, 
6H: 4 cases DR &  









last 2 years 
excluded 





Not provided 1 death- cause not 
reported 
1255 completed, 28 did not. 
Levels of acceptability, adherence 
and IPT completion were found to 




1922 ≥ 15, Black 
African 
 
No Yes TST Not 
done 
6H300 ART+IPT vs ART: aHR:0.40; 
(95 % CI: 0.18- 0.87)  
On ART, no IPT: aHR: 1; No 
ART, no IPT: aHR: 1.36 
(0.97, 1.91) 
No ART, + IPT: aHR- 1.86 
(0.68, 5.10)  
 
258 cases reported as 
either developed TB 
or deceased (13.4 %) 
IPT uptake 374 (19.4 %)  
The IPT-specific benefit in 
patients not on ART not assessed 













IPT regimen IPT outcome 
TB incidence/P100PY, IR, 
























IPT vs no IPT: 
aHR-0.43 (0.19-0.99) for 
those with positive IGRA. 




probability of death 




 Early ART+IPT 
↓severe HIV-related 
illness in by 44% and 
all-cause mortality by 
35% 
Risk of death 35% 
decrease compared to 
deferred group. 
 
Early ART effect:  
@M12-84%VL undetectable & 
@M24- 83%VL undetectable. 
Overall, CD4 remained>500 
cells/mm3 for 51% of the time.  
Cumulative probability of grade 3 




Ethiopia, 2015  
Assebe (80) 




No Not done 6H300 vs no 
IPT 
IR:  
IPT arm- 2.2/100PY (1.29-
3.82);  
no IPT= 5.06/100PY (3.65-
7.02);  
overall TB incidence 
=3.78/100PY.  
aHR 2.02 (95% CI,1.04 -3.92) 
TB free survival in IPT group 
at 36m=93% and  
no IPT group=87% 
No IPT group had 2X higher 
risk for TB than IPT group 
 
Not provided Predictors of high TB risk: 
WHO stage 3 or 4 
 CD4<350 cells/mm3 and 350-
499 cells/mm3 












IPT regimen IPT outcome 
TB incidence/P100PY, IR, 










≥ 15, Black 
African 
Yes Yes not 
reported 
6H300 Not provided Not provided Findings for children not included 
here 
73.7% uptake of IPT- of these 
88.2% completed course; patients 
on ART at IPT initiation were 
more likely to complete IPT than 
those who were not (89.2 vs. 






≥ 16, Black 
African 
Yes, n=24 
within last 6 
months 
Yes 217 TST 
(+), 47 
converted 
to (+) at 
next TST 6 
months 
later 
36H300 5 (1.7%) initiated TB 
treatment  
0.7/100 
person-years (95% CI 0.3–
1.7/100PY).  
2 DS PTB , 1 TB spine, 2 INH 
mono-resistance 
N= 5 (1.7 %)  
 
Toxicity reported in year 1= 5.6% 
(15/286), year 2= 2.0% (5/253), 
year 3= 0.9% (1/234)  
286 (99.3%) started IPT: 253 
(87.8%), 234 (81.3%), and 228 
(79.2%) were still on IPT after 
48, 96, and 144 weeks. 
40 patients did not complete IPT:  
n=21 defaulted (17/21 defaulted 
ART too) n=16 toxicity, n= 2 
stopped IPT after 6 months in 
error instead of 36 months. 
N=9 patients (3.1%) transferred 
out while on IPT. Age, high CD4 
at IPT entry, no adverse event and 
clinic were associated with better 
retention (p< 0.001).  
 
Ivory Coast, 
2017 Badje (50) 


















37% reduction in 
mortality; absolute 
reduction of 
–2.79% in the 
probability of 
mortality 6 years 
after enrolment 
First RCT to demonstrate that IPT 
↓mortality in adults on ART with 
high CD4 cell counts 
Max benefit achieved if ART and 





Key: H=isoniazid, R=rifampicin, Z=pyrazinamide, E= ethambutol, P=placebo, PY=person years; P100PY= per 100 person years, OI=opportunistic infection; HR=hazards ratio; aHR=adjusted 
hazards ratio; CI= confidence interval, IP=intensive phase, CP= continuation phase, DOT= directly observed therapy, IR= incidence rate, IRR= incidence rate ratio; HR= hazards ratio, 
PT=preventive therapy; GI=gastrointestinal; LTFU= lost to follow-up; Hb=haemoglobin, 6H300= 6 months of isoniazid at 300mg where 6 is duration in months H is the drug (isoniazid) and 






Resistance to INH  
Continued surveillance for isoniazid resistance is essential. Balcells et al.(14) carried out a systematic 
review of 13 studies spanning a time period from 1951-2006 on resistance data collected from 
approximately 35000 patients on INH or placebo. Three of the 13 studies included HIV infected people 
from Africa (Zambia, Uganda and Kenya). The review highlighted the lack of INH resistance data. The 
relative risk was found to be 1.45 (95% CI; 0.85-2.47); similar in both HIV positive and negative 
patients and therefore indicative of no increase in INH resistance. Since the absolute risk of INH 
resistance could not be ruled out, it was put forward that active TB had to be excluded prior to IPT 
initiation and monitoring for INH resistance needed to continue.  
 
In 2010, Van Halsema et al. studied TB outcomes in miners following exposure to IPT in the Thibela 
study (35). They reported the following INH resistance levels: 12.1% in first time TB cases and 7.7% 
among retreatment cases; the control group used in this study, consisting of TB cases identified in the 
Thibela study control cluster cohort, had 6.0% and 18.7% respectively in the first time and retreatment 
TB cases. The prevalence of isoniazid resistance among those exposed to IPT was similar to results 
obtained in a survey in the 1990’s of 7.3% in first time TB cases and 14.3% in retreatment cases. The 
conclusion was that INH resistance after IPT was found to be similar to that of the background resistance 
and so fear of INH resistance should not hamper efforts to scale up IPT. 
 
The South African Tuberculosis Drug-Resistance Survey 2012-14 (83) reported an increase in both 
Rifampicin [from 3.4% (95% CI: 2.8%-3.9%) to 4.6% (95% CI: 3.5%-5.7%)] and INH [currently 9.3%; 
95% CI: 7.9%-10.7%] resistance from the previous survey in 2002. INH mono-resistance was up to 
4.9% (95% CI: 4.1%-5.8%) from 2.7% (95% CI: 2.2%-3.2%). Fear of INH resistance remains a 
hindrance to fast tracking IPT implementation as prescribers still perceive IPT to perpetuate INH mono-
resistance. The report also pushes for risk benefit analysis of IPT to investigate its contribution to the 
increase in INH mono-resistance. It should be noted that resistance levels reported in this survey are 
after 10-year time period and IPT uptake in SA has increased only in the last few years.  Other factors 
should also be considered when investigating the contributing factors to INH resistance. However, a 
risk benefit assessment of IPT in the SA context is highly warranted to further inform relevant 
stakeholders and policy makers. 
 
Adherence to IPT  
Table 5 summarise studies in SSA that reported data on IPT adherence, either by pill count, patient 
recall, course completion, pharmacy refill or clinic visit attendance. In 2007 reports on poor adherence 
to IPT at proTEST study sites in Zambia and South Africa cited socio-economic reasons such as 




through the state sector and the benefit of ART use with IPT was not known. However subsequent 
studies conducted in Botswana (48) in 2010 and in Ethiopia (84) in 2014 both found ART to improve 
and enhance adherence to IPT. In addition the study in Ethiopia identified other predictors of both 
adherence and non-adherence where being adherent was supported by receiving information on IPT and 
factors that contributed to non-adherence included forgetfulness and to a lesser extent illness, side 
effects, stigma and being away from home (84).  
When the recommended 6 month INH course for IPT was studied in comparison to other regimens, 
researchers who conducted the study in 2011 reported that adherence was higher in the regimens that 
were of shorter duration viz. 3 months of rifapentine (RPT) and INH (76). The BOTUSA study showed 
a statistically significant association between IPT and concurrent ART use (48). Other recent studies of 
combined IPT and ART use in 2015 also showed high adherence for the duration of follow up at levels 
greater than 90% (31, 85). The studies included in Table 5 are representative of populations from high 
TB and HIV burden countries in SSA with some ART coverage in the more recent years and thereby 
able to reflect IPT adherence outcomes in the context of ART use. 
  
Makanjuola et al. conducted a qualitative systematic review on factors associated with IPT adherence 
(86). Five themes were highlighted as findings: personal beliefs, issues related to HIV and ART, socio-
economic issues, family and other psychosocial issues, and healthcare provider relationship. The fear 
of experiencing stigma related to being HIV positive prevented some patients from coming forward and 
taking up IPT. The qualitative data analysed in this review highlighted that there is overlapping 
interaction between multiple factors that impact on adherence. The authors recommended that these 
findings be taken into consideration by the various decision makers in order to engage patients better 






Table 5: Summary of reviewed articles on IPT adherence 
Study Age  
Race 
Sample size (n) 
Previous 
TB 
ART use IPT regimen Adherence 






No 3H300, 6H300, 12H300 
or P 
Overall not reported, majority were ‘compliant’ 
Above 80% was considered adherent  
Kenya, 1997 
Hawken (72) 
≥ 18 years  
Black African  
n=684 
No-excluded None 6H300 vs P  Missed 1 week= 42%; 1-4 weeks= 27%, >5weeks= 31% 
Uganda, 1997 
Whalen (73) 
≥ 18 years 
Black African 
n=2736 
No-excluded No-excluded 6H300, 3RH600/300, 
3RZ600/2000, 6P  
Monthly visit X 6, then 3 
monthly 
Attendance at scheduled visits, , Patient self- report, urine test for INH 




≥ 15 years 
Black African 
n=1053 
Not reported No 3RZ600/3500 twice 
weekly VS 
6H900 twice weekly 
VS placebo (3P twice 
weekly or 6P twice 
weekly)  
Drug calendars issued to patients 
Pill collection and patient report, considered compliant if collected all their tablets 
and adherence ≥ 80%, overall compliance in study was 74% - of which 92% were 
defined probably compliant and 8% possibly compliant 
Botswana, 2010 
Mosimaneotsile 




Yes Yes 6H: 300mg: 30-49 kg 
400mg: ≥ 50kg; then 
changed in Jan 2006 – 
300mg all 
Adherence measured by attendance to clinic visits= 86% 
Pill counts done at M1, 3 & 6: 100% all 3 months =27%; >90% all 3 months 
=77%; >80% all 3 months = 91%; <80% any month= 9%; ART enhanced IPT 
adherence 
 
South Africa, 2011 
Martinson (76) 
≥ 18 years 
Black African 
n=1148 
Not reported No 3RPT900/ H900, 
3R600/ H900, 36H300, 
6H300 
Adherent if ≥ 90% 
RPT/H= 95.7%; RH= 94.8; 6H= 83.8%; 36H= 60.3% 
Botswana, 2011  
BOTUSA Study (77) 





Yes 6H+30P vs 36H 
300mg <50kg; 400mg 
≥50kg 
Overall adherence to clinic visits over 3 year follow up: 6H: 78%; 36H:77% 
Botswana, 2011 
Samandari 
BOTUSA Study (34) 
≥ 18 years 
Black African 
n=1995 




6H+30P vs 36H 
300mg <50kg; 400mg 
≥50kg 




Study Age  
Race 
Sample size (n) 
Previous 
TB 
ART use IPT regimen Adherence 




Not reported Yes N/A Survey: Adherence defined >80% of the prescribed INH in the past 7 days prior 
to survey. Self-reported adherence= 89.5%. Factors associated with adherence: 
People on ART, had IPT ≥ 5months, had info on why they took IPT, remembered 
taking a dose within last 1-11 hours prior to survey. Factors associated with non-
adherence: Forgetting =45.2%, Drug out of stock =11%, Side effects =16.4%, too 
ill to take meds =16.4%, away from home=5.5%, Stigma=5.5%. 
Tanzania, 2015 
Shayo (79) 





last 2 years 
excluded 
Yes 6H300 for adults Data on adults ≥ 18 years old only reported in this table 
Adherence defined as ≥ 90% 
Overall mean with SD 98.9% (±2.9), 18–29 years (98.3), 30–49 years (98.8) ≥ 50 
years (98.5 %) [p = 0.011] 
Ivory Coast,2015 
Temprano Study (31) 
≥ 18 years 
Black African 
n=2056 
Yes Yes- early & 
deferred 
6H300- no IPT, early IPT, 
IPT deferred or none 
(ART+IPT)  
Reported as completion rate: 94% completed IPT early group and 93% completed 
IPT deferred group. N=22/927=2.3% discontinued IPT for personal non-medical 





≥ 16, Black 
African 
Yes, n=24 
within last 6 
months 
36H300 Adherence assessed by pill count, urine test and interview  
Urine sample 1 – 30 hours after INH dose 
Positive result for INH was 80.1% (95%CI 76.9–82.9%).  
Negative result: only 11/141 patients reported no INH dose 
in the past 24 hours. 
Proportion of positive urine tests and pill count indicated decreasing adherence 
over time (test for trend P= 0.04 and 0.12) 
Reports of missed doses seemed to improve over time. The 
main reason given for missed drug intake: forgot, not having the drug 
with them, lack of food, feeling unwell, running out before next appointment date. 
Key: H=Isoniazid, RPT=Rifapentine, P=placebo, SD=standard deviation, 6H300= 6 months of isoniazid at 300mg where 6 is duration in months H is the drug (isoniazid) and 






IPT adverse effects 
Data has been collected on the adverse effects associated with use of INH for IPT from as early as 1982 
and up to 2016 in Table 6. The International Union Against Tuberculosis (IUAT) were the first to report 
that IPT associated hepatitis most frequently occurred with the first three months of IPT start (71). This 
finding was also demonstrated years later in the BOTUSA study in Botswana (48). Interestingly, the 
position of the IUAT researchers was that IPT use resulted in more TB cases prevented per case of 
hepatitis caused. While earlier IPT recommendations warned against INH-induced hepatitis for those > 
35 years of age, these concerns were laid to rest by Tedla et al. in 2010 and Gray et al. in 2016, that 
showed no significant interaction between hepatitis and age > 35 years while on IPT (87, 88).  
 
Martinson et al. compared three preventive therapy regimens in 2011 and showed that the longer 
duration regimen of 36 months of INH resulted in more adverse effects than shorter courses of either 
INH alone for 6 months or ultra-short courses of INH in combination with other drugs (76). Currently 
published literature demonstrates overall safety and tolerability of INH when used as preventive 
therapy; however, the majority of the studies in Table 6 were among HIV infected people not on ART. 
Only one study by Tedla et al. showed (using data from the BOTUSA study) that any association 






Table 6: Adverse effects associated with IPT  
Study Age 
Race 
Sample size (n) 
Previous 
TB 
ART use IPT regimen Toxicity 








No 3H300, 6H300, 12H300 
or P 
5 years of follow up  
Hepatitis [IPT: 0.5%, P: 0.1%]  
Most common within first three months of IPT. 6H300 prevented more TB cases 
(9.3/1000 persons TB cases prevented vs placebo in year 5) per case of hepatitis 
(3.6/1000 persons hepatitis cases incurred in excess over placebo in year 5) caused.  
Benefit-to-risk ratio was 2.6 at year 5 for 6H300 
Kenya 1997 
Hawken(72) 





None 6INH300 vs P n=18(IPT), 12(P): AST/ALT>2ULN 
PN=8(IPT) 
Treatment stopped due to toxicity n=11(IPT), 5(P) 
Uganda 1997 
Whalen (73) 








RZ600/2000, 6P monthly 
visit X 6, then 3 monthly 
304 AE, 43 discontinued treatment, AE frequency was greatest in the RZ arm 
Most common AE: Rash/pruritus=25, NV=8. Less common: arthralgia, 










No 3RZ600/3500 twice 
weekly VS 
6H900 twice weekly VS 
placebo (3P twice weekly 
or 6P twice weekly)  
3% adverse drug reactions:  




South Africa 2003 
Churchyard (69) 
≥ 18 years 
Black African 
n=559 
Yes No Indefinite H300 Rash: 2 (re-started) + 3 (stopped),  
abdominal pain: n=1 
nausea: n=1 
 no hepatitis or PN 
South Africa 2005 
Grant (36) 




Yes No 6H300 or 12H00 if co-
infected with silicosis 
N=9 stopped IPT due to rash n= 7, rash + mild hepatitis n=1, 
mild PN n=1, and 2 of the 9 restarted; 
13 others cases had PN and 9 had rash but all completed IPT 
Tanzania 2008  
Ex-Dar Dar Study 
patients Munseri (75) 
≥ 18 years 
Black African 
 n=1932 
NK/NR No 6H300 INH toxicity n= 3: PN n= 1, hepatitis n =2  
INH intolerance:  nausea = 4 






Sample size (n) 
Previous 
TB 
ART use IPT regimen Toxicity 
Botswana, 2010  




Yes Yes 6H open label phase of 
BOTUSA Study, Initially 
weight dependant dosing: 
300mg: 30-49 kg, 400mg: 
≥ 50kg; then changed in 
Jan 2006 to 300mg all 
28 severe AEs (1.4%) 
Hepatitis n=19 (including 1 death) 
 Rash n=5 
 Seizure n=2 (1 suicide attempt by INH overdose) 
 Other n=2 
Botswana, 2010 
BOTUSA Study (87) 
18-70 years  
Black African 
 n=1995 
Yes Yes 6H+30P vs 36H 
300mg <50kg; 400mg 
≥50kg 
AST/ALT levels: 6H grade 1= 354(87%), grade 2 = 34(8.4%), grade 3= 15(3.7%).  
INH induced hepatitis= 1.1% with 1 death hepatic encephalopathy. In bivariate 
analysis CD4 < 200 cells/mm3 associated with INH induced hepatitis (RR: 2.80; 
95%CI, 1.14–6.84); multivariate showed it was ART not CD4. Age > 35 was non-
significant with INH-hepatitis (RR, 1.56; 95% CI, 0.64–3.82). 1.6-fold higher risk 
for INH-hepatitis for those on ART+ IPT (not significant).  
34% reported alcohol use and 5.6 % traditional medicine- authors feel this was 
underreported. 





NK/NR No 9H300 132 AEs (0.54%), 1 resulted in death (overall IPT risk 0.004%) 
Rash n=61 (0.25%) –median 20 days after started IP, graded mild or moderate, 
PN n=50(0.21%)-median 34 days after IPT start, graded mild or moderate 
Hepatoxicity n= 17(0.07%), all grades; median 117(2-263) days after IPT start 
Convulsions n=4 (0.02%), 1 death, reported alcohol use  
Botswana, 2011 
Samandari 
BOTUSA Study (34) 






6H+30P vs 36H 
300mg <50kg; 400mg 
≥50kg 
Toxicity reported to be similar in both arms 
First six months: Control arm n= 10, 1.4 % (hepatitis=10, rash=2 and seizures=2); 
IPT arm n=16, 1.6% (hepatitis=10, rash=1, seizure=1, tinnitus=1, headache=1) 
After 6 months: Control Arm n=7, 1%; IPT arm n=11, 1.3% (p=0.36) 
Overall: INH induced hepatitis n= 29 for 3100 PY of INH use 
 
South Africa, 2011  
Martinson (76) 
≥ 18 years 
 Black African 
 n=1148 
NK/NR No 3RPT900/ H900, 3R600/ 
H900, 36H300, 6H300 
AST/ALT grade 2&3: RPT/H:  1.5%, RH: 2.4%, 36H300: 28.0%, 6H 5.5% 
(P<0.001 for 36H vs 6H) 
South Africa, 2014  
Rangaka (78) 
≥ 18 years 
Black African 
 n=1329 
Yes Yes 12H vs 12P; Dose: 
200mg < 50kg and 
300mg ≥ 50kg 
ALT ≥ grade 3 (n=34); of which 29 stopped IPT - risk ratio 1·9 (95%CI 0·90–
4·09) 
PN≥ grade 2 (n=3) 
Rash ≥ grade 2 (n=2) 
Tanzania, 2015 
 Shayo (79) 











Sample size (n) 
Previous 
TB 
ART use IPT regimen Toxicity 
Ivory Coast, 2015 
Temprano Study (31) 
≥ 18 years 
Black African 
 n=2056 
Yes Yes 6H300- no IPT, early 
IPT, IPT deferred or none 
(ART+IPT)  
UK cause of death (n=1) 
Elevated AST n=6 
Psychiatric side effects n=4 
Pruritus n=2 
Australia, 2016 
 Gray (88) 





9H300 vs 4R 74% completion rate on H (IPT) and 86% on RIF 
33% IPT and 23% on RIF experienced some LFT abnormality 
AST ≥ 5ULN =3%  
There was no association found with age but there was an association between 
baseline liver abnormality and developing drug-induced hepatitis during PT. 
Significant predictors of liver dysfunction during PT were risk factors for liver 
disease (p= 0.03) or abnormal pre-therapy LFT (p < 0.001). 
3% stopped IPT due to INH-induced hepatitis 
overall 17% (3% grade 3/4 and 14% grade1/2) 
 Males were twice as likely to have abnormal LFTs (p=0.02) 
No association between degree of LFT abnormality or age ≥ 35 with resolution of 










36H300 Hepatotoxicity n=3 (1.0%), 2 were severe (1 ALT 5–10 ULN, 1 jaundice) and 1 
mild.  
No liver tests to confirm the diagnosis.  
Rash n=2, itching n=1, peripheral neuropathy n=2, nonspecific weight loss n=3, 
psychotic decompensation n=1, vertigo and nystagmus n=1. 
16/22 patients had IPT stopped: 1 was found dead at home 2 months after IPT 
stopped, and 1 pregnancy resulted in stillbirth.  
Side-effects reported during adherence assessment interview at the 2 clinics 
decreased from 19.0% (16/79) and 50.0% (25/52) at 6 months, to less than 1% 
after 30 months.  
H=Isoniazid, RPT=Rifapentine, R=Rifampicin, P=placebo, PY=person years, liver function test= LFT, AST= aspartate aminotransferase, ALT= alanine transaminase, ULN= 
upper limit of normal, NK/NR=not known or not reported, GI= gastrointestinal, PN=Peripheral neuropathy, UK=unknown, AE=adverse events, CI=confidence interval, 




 IPT policy and implementation 
While global support for IPT implementation increased during the period 2002 to 2009 (Table 7), the 
need remains for improved operational systems, continuous monitoring and evaluation of IPT 
implementation outcomes and the subsequent impact on both patients and staff on the ground level. The 
reporting mechanisms in place should efficiently disseminate these findings to facilitate reviews and 
evidence-based updates of existing IPT policy. The following barriers to IPT implementation were 
identified by Getahun et al. (19): 
• Government- lack of leadership, TB care being ignored by HIV services, absence of or weak 
national policies, minimal collaboration between TB and HIV services, fear of INH resistance 
• Service delivery related to TB diagnostics, TST administration, poor client adherence 
• Supply related-lab supplies; poor TB and HIV supply management, TST supply, INH supply 
• Healthcare worker (HCW) related – lack of training and supervision, poor perception of IPT, 
fear of INH toxicity and resistance, poor communication and inter-referral 
• Health information system related – lack of adequate standardized indicators, monitoring and 
evaluation 
• Health system financing related – allocation of funds and competing priorities for resources 
 
Recommendations to improve IPT uptake by the authors (19) included: integrated operational approach 
between national TB and HIV programmes, simple TB symptom- based screening algorithms, patient 
monitoring and education to reduce the risk of INH toxicity and increase adherence, ensure effective 
INH access and supply system, set up monitoring and evaluation systems that are in line with 
internationally recognised systems and indicators, engaging and empowering affected communities in 
screening, prevention and education activities. 
 
A survey was conducted amongst HCW at public hospitals to assess barriers to IPT implementation 
with regards to: leadership and governance, service delivery, supplies and products, health workforce, 
heath information system, and health system financing (89). About 22% physicians, 38% TB clinic 
nurses 39% HIV clinic nurses responded. Main barriers identified were: unclear national policy: 60%; 
fear of INH resistance: 52%; fear of poor adherence by nurses: 30%. Clinicians were more reluctant to 
implement IPT due to fear of increasing INH resistance (81%) whereas nurses were reluctant 
implementers due to the perceived higher workload. Hospitals implementing IPT programmes were 
motivated by (1) knowledge that IPT can prevent TB (63%), (2) the following of national guideline 
(34%), (3) concern for TB prevention even after the expansion of access to ART (32%). The authors 
felt that new evidence-based information may improve HCW’s understanding of IPT, and subsequently 





Chehab et al conducted a cross sectional study amongst NDOH clinics in SA (90, 91). They found that 
there was a lack of TB/HIV committees as well as trained staff or adequate access to guidelines; there 
was fear of INH resistance amongst HCW, and IPT counselling did not cover all essential topics. 
Amongst PEPFAR-assisted sites in South Africa, patients initiated on IPT increased from 1% in 2010 
to 10 % in 2011(92). The availability of staff training, clinic registers, assurance of INH drug supplies 
and routine quarterly evaluation by the NDOH TB program contributed positively to this increase in 
IPT initiation. However, IPT adherence as well as IPT outcomes was not assessed. Lester et al (93) 
reported barriers to IPT implementation in SA, similar to those discussed previously. A survey 
conducted amongst clinic staff and patients in Gauteng highlighted the similar trends of lack of 
knowledge and experience amongst HCW; prescribers were unaware of IPT benefits and unclear about 
guidelines; they also believed that TB screening tools were inaccurate in HIV patients and there was 





Table 7: Summary of IPT implementation and policy articles 
Study Sample 
size 






59% 41 countries responded 
51% had IPT national policy 
28% implemented nationwide – of which a median of 3% were ART clinics and 50% 
TB clinics that provided IPT. Challenges & concerns included:  
Inadequate intensified TB case-finding, unable to exclude active TB, performing 




N/A Burden of LTBI greatest in Asia, West Pacific region, Africa and Mediterranean. Re-
infection is a major problem in African settings. Benefit on mortality only seen in 
TST+ HIV infected people. IPT was found to reduce TB incidence, is safe and 




N/A SA has highest IPT 372994 patients in 2011, however 80% with HIV still require it 
strengthen research & development; training funding from DOH; research and 
evidence –based planning driven PHC re-engineering 
Ati-Khaled 
2009 (96) 
N/A  Major barriers to IPT scale up: who takes responsibility of it, how to identify LTBI, 
how to rule out active TB, appropriate length and duration of treatment effect. 
Suggestions made by authors include: HIV services take responsibility of IPT 
provision; set up operational programmes to observe how best to implement routine 
IPT, develop algorithms for IPT eligibility, structured pre-ART programmes; patient-





22+20 10 HIV clinics- 22 staff and 20 patients had a survey on their knowledge and 
experience on IPT and related barriers. Findings: staff lack of knowledge due to low 
use of IPT in routine practice, unaware of efficacy, afraid of missing active TB and 
promoting resistance to INH, operational blocks included access to TB testing 
equipment, facilities and timely receipt of results. Patients surveyed never heard of 
IPT and when asked about pill burden and other socio-economic barriers responded 







1670 29 PHC HIV clinics; staff IPT training intervention on IPT; findings post training: 
85% completed IPT; 1.2% had adverse reactions and stopped therapy; IPT 
completion was higher if patients were on ART compared to no ART. (87% vs 79%). 
Time to TST done and starting IPT were improving but still long. Combination of 
advocacy, service integration and training was successful in this setting. 
Eldred 2010 
(26) 
N/A Evidence to support implementation from Consortium to Respond Effectively to the 
AIDS-TB Epidemic (CREATE) projects: a) Thibela TB an implementation trial of 
community wise IPT among gold miners- enabled more ICF for active TB then 
existing health care services; b) THRio study – combined ART and IPT more 
effective; c) ZAMSTAR study- Zambia and South African sites for IPT pilots, ICF, 
social mobilisation, access to better diagnostics  
Getahun 
2010 (19) 
N/A Analysis of WHO databases on HIV/TB collaborations. 19-fold increase in global 
implementation from 2002-2009. Barriers included: no supportive government policy 
in place, poor service delivery, stock availability, HCW lack of training and 
knowledge, poor resources unable to establish monitoring system, lack of utilization 
of funds to scale up IPT. Solutions suggested: set up national policies and 
programmes, algorithm for TB screening and IPT eligibility, patient education and 
monitoring, effective access and supply of drugs and suitable dosage forms, design 





2512 46% uptake 




2512 855 facilities with Integrated TB/HIV offered IPT vs 59% not integrated 
29% felt no guidance or commitment from authorities 
21% INH resistance concerns 
64% had latest guidelines 










N/A IPT implementation in South Africa from January 2010-March 2011 in PEPFAR-
assisted sites. 14-fold increase in patients started on IPT -went from 1% to 10.5%, 
just after new SA guidelines for IPT released. Authors reported that creation and 




N/A Systematic review on implementation of 5 WHO TB activities, one being IPT. The 
authors found major gaps in available evidence for scale-up the 5 TB interventions. 
Lacking at country level suggested that national implementation of these 
interventions would be precluded. They called for operational research in 




N/A Review of literature 1995- 2013 and included data on mortality, morbidity, cost 
effectiveness and retention in care of provision of IPT in low- or middle-income 
countries. This review did not consider other optimal drug regimens, duration of IPT 
efficacy, IPT adherence, side effects or INH resistance. The authors identified 
research gaps: duration of IPT protective effect varies according to burden setting, no 
clear definition of the optimal duration of course (short, lifelong, or repeated), 
possible INH resistance in programme, other shorter course preventive therapy drug 
regimens comparable in safety and efficacy and also in which settings these regimens 





198 HCW from 95 public hospitals responded to questionnaires. Lack of knowledge and 
concern about INH resistance were key barriers to implementation at hospitals where 
IPT was not implemented; having knowledge of the effectiveness of IPT as well as 
knowing and following national IPT policy were motivators at hospital with IPT 
implemented. Authors emphasised dissemination of and access to national policies 




N/A 6 SA studies including 4 RCTs – only some showed IPT benefit that was significant. 
IPT combined with ART lowered TB incidence. Thibela Tb found 7% more TB in 
IPT arm at screening than standard of care. Rangaka et al. diagnosed more TB cases 
at baseline than the cases prevented by IPT. 
2015  
Akolo (103) 
N/A Counteracted the myths around IPT as flows: TB screening is effective in ruling out 
active TB, chest x-ray not compulsory for initiation, IPT does not promote INH 
resistance, IPT has combined effect with ART in reducing TB, adherence to IPT is 
good, IPT is safe, tolerable, cost-effective, recommended for use in children, TST not 
a requirement for initiation. 
Key: RCT=randomised control trials, HCW=healthcare worker, SA= South Africa, PHC= primary health care, 





1.4 Description and significance of the core research problem: Challenges of rolling out 
IPT in South Africa 
 
Several studies published since 2010 have demonstrated the safety and effectiveness of integrating IPT 
and ART in patient care thereby improving both HIV and TB outcomes. (29, 32, 48, 59, 68, 104). 
However, implementation and IPT uptake has been relatively slow (12, 105). The reasons for the slow 
roll out of IPT could be related to the many HCW-related and patient-related barriers to IPT 
implementation.  
 
Barriers to IPT implementation reported by HCW include potential long duration of treatment (90, 92, 
93, 106-108), fear of INH stock outs (109) and fear of INH resistance developing (110). The lack of 
HCW experience (93, 109) as well as availability of IPT guidelines and training (90, 109) have also 
been previously observed. HCW also remain unconvinced of the effectiveness of IPT (93, 111) and 
subsequently lacked in reinforcing adherence among patients started on IPT (109). Non integration of 
HIV/TB services and having to refer patients out to other TB facilities for care was also reported as a 
contributing barrier for IPT implementation (93). 
 
Qualitative data on IPT use have identified a few patient related barriers to IPT uptake and 
implementation. These include stigmatization (86) linked to HIV as well as non-disclosure of HIV 
status (86, 109). Other barriers related to IPT use are that patients may not know much about IPT nor 
fully understand the benefits of taking IPT (86, 93, 109, 112). 
 
Despite the barriers mentioned the use of IPT has now gained momentum in recent years (92). To 
improve uptake and as part of the testing algorithm for HIV post-test counselling outlined by the SA 
national HIV testing services in its policy (113), clients are offered IPT as part of a comprehensive 
package of care, in keeping with in country and global recommendations. There has also been 
recommendations to update policy guidance as more evidence emerges on best practices to inform IPT 
provision (107). As of 01 September 2016, SA DOH has adopted the Test and Treat campaign for 
immediate ART initiation for a positive HIV diagnosis irrespective of CD4+ T-cell count. It is important 
to factor in what impact this would have on ART and IPT delivery. By the end of 2015, over 3.4 million 
of the 7 million HIV infected people in SA had access to ART (114). Using these estimates translates 
to approximately 3.6 million patients already eligible for immediate ART initiation, over and above the 
new HIV infections diagnosed. Once active TB is ruled out, then millions of people potentially become 
eligible for concurrent IPT initiation with ART or IPT provision following ART initiation. 
Consequently, this may result in further operational challenges for ART and IPT delivery increasing 





Furthermore, with the updates to the South African guidelines since 2013 and 2015, patients can now 
receive IPT up to a maximum of 36 months’ duration. This means that IPT programmes need to be 
maintained and monitored for a longer period of time so that the effectiveness of IPT as an intervention 
for TB prevention can be constantly evaluated. In the context the of scaling up treatment for TB/HIV 
integration lack of infrastructure and trained, experienced staff are reported barriers to effective progress 
in service delivery efficiency (115). Similar challenges will apply to large scale IPT provision (12). The 
establishment of a multi-disciplinary team approach to IPT provision within an integrated healthcare 
system is a very promising strategy. Various health care professionals including nurses, counsellors, 
pharmacists, clinicians as well as others, may contribute operationally to the landscape of combined 
HIV treatment and TB prevention services. For example, the pharmacist could play a significant role in 
staff training, patient education, counselling, assist with identifying symptomatic patients with 
presumptive TB, as well as be able to contribute to monitoring adherence to ART, IPT and clinical 
outcomes of IPT use. This task shifting or sharing of responsibilities to support IPT provision could 
lead to enhanced IPT uptake and improved quality of care. Innovative prospective steps need to be taken 
to ensure improved efficiency for long term sustainability of large scale ARV, TB treatment and TB 
preventive therapy provision in South Africa. 
 
1.5 Problem statement 
South Africa has dual epidemics of HIV and TB. Rapid re-infection and relapse rates of TB extenuate 
the circumstances and hinder any progress made towards TB prevention. HIV/TB service integration 
is the gateway to successful implementation of TB preventative based interventions such as IPT. 
However, the majority of data published on IPT was obtained from research conducted in the pre-
ART era or in ART populations with no past history of TB, previous TB exposure being grounds for 
exclusion from IPT. There is a resultant paucity of data on IPT outcomes and effect on TB incidence 
in ART and TB treatment experienced populations. 
 
 1.6 Study hypothesis 
The roll out of IPT within an ART programme, in a high TB burden area with limited resources, 
amongst TB treatment experienced patients will decrease TB incidence. 
 
1.6.1 Study Aims 
• To retrospectively report uptake and clinical outcomes of an IPT programme in a resource –
limited urban clinic located in a high TB burden setting amongst HIV infected patients 
receiving ART. 




implementation and monitoring adherence to IPT.  
 
1.6.2 Primary Objectives  
• To assess the design and implementation of IPT roll-out within an ART programme 
• To report on the outcomes of the IPT roll-out including: 
o  IPT uptake, contribution of background TB to IPT ineligibility 
o Gender differences in IPT uptake 
o Assess IPT implementation among patients with a past history of TB treatment  
o Assess adherence to IPT 
o Assess adverse effects related to IPT 
o Describe the pharmacist’s role in a multi-disciplinary approach to IPT implementation 
and roll-out 
 
1.6.3 Secondary Objectives 
 
• To report on areas of implementation that require strengthening or modification to enhance the 
quality and effectiveness of the IPT roll-out 
• To identify any trends in IPT interruption, IPT completion as well as reasons for IPT refusal  
• To determine TB incidence in patients, post IPT 
 
 1.7 Conceptual framework 
 
The following key factors that impact IPT and the relationship among them has been depicted in 
Figure 4: population, community, clinic, healthcare system, as well as patient and medication factors.  
Population Factors:  
In areas endemic to HIV and TB, the high TB transmission and re-infection rates is exacerbated by 
high HIV incidence and prevalence (116). TB prevention strategies such as IPT are necessary to curb 
growing TB incidence (38). Recurrent TB is a concern in these settings especially in a population 
where there may be a history of multiple episodes of previous TB. These population factors impact 
the duration and durability of IPT to achieve a protective effect in a region of high` TB/HIV burden. 
Community Factors:  
The stigma associated with HIV still runs strong within communities. The resultant non-disclosure of 
HIV status has a negative impact on the uptake of IPT (117) as this service may inadvertently expose 
patients to discrimination amongst family, colleagues and peers, since TB related factors are 
associated with HIV within the community. TB related stigma itself has potentially huge negative 
consequences with late presentation of ill patients to clinics thus resulting in delayed TB diagnosis 




community and possible treatment interruptions. People fear that having TB will lead to them being 
perceived in the community as being unhealthy, weak and not ‘strong’ (86, 118). 
Clinic Factors:  
The clinic environment can either promote or reduce patients’ acceptability of IPT. The already 
understaffed clinic and subsequent overworked staff results in long queues, overcrowding, and 
sometimes poor rapport between patients and staff. A lack of facilities as well as limited staff access 
to IPT training, standard operating procedures (SOP), policies and guidelines negatively impacts 
staff’s ability to adequate screen, educate and implement IPT use amongst patients (90). Patients in 
turn do not fully understand the importance of IPT for TB prevention and this may affect their 
adherence. However, some clinic environments with well trained staff, adequate privacy and well 
developed TB screening and IPT guidelines, counselling and policies in place promote an improved 
patient experience that would enhance their education, awareness and subsequent compliance to IPT 
course completion (119). It is also important to note that many clinics do not have a multi-disciplinary 
healthcare team available. This approach would provide much needed support to mainly nurse –run 
clinics and potentially result in more effective service delivery and clinical care of patients; where 
some of the burden of providing and monitoring IPT could be shifted from the clinic nurse to other 
skilled healthcare workers. 
Healthcare Infrastructure: 
Healthcare systems and infrastructure are linked to clinic capabilities to adequate roll out IPT and 
other TB prevention activities. This is dependent on having national policies and programmes in 
place, promoting integration of TB/HIV service provision (99). It is important to have systems in 
place for monitoring, evaluating IPT implementation as well as consistently reporting to the relevant 
stakeholders to ensure targets are met and programmatic challenges can be addressed(92). 
Medication: 
There are some medication related factors to take into consideration as well. Patients on ART and 
receiving treatment for other opportunistic infections or co-morbidities may experience an additional 
pill burden with IPT, and should be monitored and adequately counselled on side effects, dietary 
precautions if required, as well as other drug-drug interactions. In contrast, it should also be 
considered that being on lifelong ART would promote adherence to IPT (48). 
Patient Factors:  
The socio-economic status of patient’s impacts on uptake, compliance, awareness and understanding 
of IPT as well. Travelling long distances to the clinic, migrating out of town for job opportunities, 
non-disclosure at work are some of the challenges that patients may face (75, 118). In addition, 




complications, and concern about family/spouse support (75, 117). A patient who is well counselled 
and understands the importance of IPT would be more adherent due to his/her belief in protective 
effects of IPT (120)


























































2. CHAPTER TWO: METHODS 
 
2.1 Study design and period 
This study assessing IPT implementation was designed as a secondary analysis of prospectively 
collected clinical and demographic data. Data was extracted from clinic files, Case Report Forms 
(CRFs) and computerized pharmacy dispensing records from the parent study, CAPRISA 005 TB 
Recurrence upon Treatment with HAART (TRuTH), conducted during the period October 2009 to 
October 2013. The TRuTH study was a prospective cohort study assessing TB recurrence among 
patients initiated on ART. From 2011 onwards IPT was offered to adult patients ≥ 18 years accessing 
HIV care, in accordance with national treatment guidelines.  
The independent variable for this study was exposure to IPT. The dependent variable was the 
incidence of TB in patients receiving IPT. The control variable was exposure to ART. The present 
study analysed data generated over the same time period during which the TRuTH study was being 
conducted.  
2.2 Study location 
The Centre for the AIDS Programme of Research in South Africa (CAPRISA) eThekwini Clinical 
Research Site is an urban clinical research clinic, located at Durban's Warwick Triangle, KwaZulu-
Natal which is one of the main bus and train hubs in and out of the city, making it easily accessible to 
people travelling from townships and rural areas. The site is located adjacent to the Prince Cyril Zulu 
Communicable Disease Centre offering facilities for TB/HIV care and serves the Durban functional 
region.  
2.2.1 Provision of IPT  
Programme implementation 
 All patients at the time of TRuTH study enrolment had experienced one or more previous episodes of 
TB and were stable on ART. Clinic visits were scheduled for provision of follow up care and ART 
supply every 3 months. 
A clinic assessment was conducted prior to implementation of IPT in order to design the programme 
as well as identify relevant resources. This was followed by attendance of staff, including 
pharmacists, at IPT training workshop conducted by the South African Department of Health in 2010. 
The IPT rollout was designed in accordance with then current South African guidelines and 
implemented in October 2010. Patients were screened for TB (Figure 5) and those with no signs and 
symptoms of active TB and found to be eligible, were enrolled, if agreeable, onto a six month IPT 
course. Clinic staff queries and refresher training was overseen and conducted by pharmacy staff in 




INH was prescribed using weight-dependant dosing criteria and verified at the pharmacy as described 
in the instructional memo issued in 2010 by the NDOH on implementation of IPT guidelines 
(Appendix E). The dose of INH was prescribed and dispensed as 300mg for those ≥ 60 kg, 250mg for 
50-59.9 kg, and 200mg for those weighing 40-49.9 kg. A prescription for INH (Appendix F) was 
written up the clinician at IPT initiation and thereafter completed monthly by either a clinician or 
nurse to document ‘Yes’ or ‘No’ responses to questions on the prescription related to potential TB 
symptoms. The pharmacy staff verified that this was completed in full every month for each patient to 
confirm continued eligibility to continue safely receiving IPT. Any weight changes were reviewed 
and a new INH dose was prescribed at a higher or lower dose according to the new weight-dependant 
dosing range. The pharmacy staff documented manual pill counts, calculated adherence and dispensed 
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IPT clinic visits 
INH was dispensed monthly to enrolled participants. 
Each monthly visit comprised the following step and procedures (Figure 6): 
• Vitals assessment– patient’s general health status was assessed and TB screening was conducted 
by the staff nurse.  
• Consultation – The professional nurse verified the patients continued eligibility for IPT or 
enrolment onto IPT by reviewing TB symptoms. The screening checklist on IPT side effect 
profile was assessed and counselling needs identified, if applicable. Complicated cases, TB 
suspects and potential enrolments were referred to the clinician for further work up. 
• CAPRISA adherence support programme (ASP) – this programme was counsellor driven and 
aided by a multi-disciplinary inter-referral system between nurse, clinician and pharmacist. The 
pharmacist assisted with drawing up and reviewing counselling material and resources used on an 
ongoing basis, related to INH side effect management, adherence issues and motivational 
messaging and ensured that all relevant clinic staff were trained. 
• Pharmacist role – the pharmacist reviewed the TB symptom screening checklist and confirmed 
eligibility for IPT on a monthly basis. In addition, the pharmacist monitored the patient weight 
and related INH dosing, conducted INH pill counts, identified patients with adherence issues that 
required intensified counselling, dispensed and counselled on appropriate INH use and storage. 
Patient questions, queries or concerns were communicated by clinic staff to the pharmacist and 
dealt with during face-to-face patient counselling in addition to ASP as pharmacy was the last 





Figure 6: IPT clinic process flow 
 
2.2.2 Patient clinical management  
TB screening was conducted at every follow up visit (Figure 7). If a patient was symptomatic, 
investigations for active TB were initiated. If active TB was diagnosed, INH was stopped and the 
patient was referred to the adjacent TB facility located next to CAPRISA to initiate TB treatment 
immediately. If patient was asymptomatic, they were screened for INH side effects. Pyridoxine was 
prescribed for peripheral neuropathy, the development of a rash was treated symptomatically if it was 
not severe, or referred for further care if severe. Patients were screened for hepatitis and liver function 
was monitored whilst on IPT. The pharmacy staff calculated monthly adherence to INH and advised 
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Figure 7: Algorithm for patient management during IPT follow up visits (121) 
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2.2.3 Monitoring and evaluation 
Pharmacy compiled IPT dispensing statistics as well as data related to IPT interruptions including the 
duration of the IPT interruption. The pharmacist also verified IPT course completion and double 
checked the duration required by patients to complete IPT course or re-start IPT after course 
interruptions in accordance with guidelines in effect at the time. On a monthly basis, IPT dispensing 
statistics were circulated to the rest of the clinic team as well as relevant reporting authorities using 
the template provided by SA DOH. 
 
2.3 Study population, sample size and sampling strategy 
The masters’ candidate conducted a retrospective analysis of all records of the 402 patients with a 
previous history of TB enrolled in the TRuTH who had been receiving ART at the CAPRISA clinic 
for several years at the time of IPT programme implementation. 
 
2.4. Inclusion and exclusion criteria 
This study included adult HIV infected patients ≥ 18 years old on ART. Those with no signs or 
symptoms of active TB documented and who met the criteria outlined in the South African IPT 
guidelines applicable at the time were deemed eligible to receive IPT while accessing care within the 
TRuTH Study. 
Those excluded from IPT initiation were those who were being investigated for active TB, clinically 
assessed to be at risk for adverse effects or those who declined IPT. 
 
2.5 Data collection 
Participant data was collected in the TRuTH study on case report forms (CRF) for routine data-faxing 
into the secure CAPRISA participant database and included demographics (related to age, gender, 
education, employment, marital status), clinical TB symptom screening, past history of TB, household 
TB contacts, haemoglobin (Hb), Alanine transaminase (ALT), aspartate aminotransferase (AST), 
fasting cholesterol, liver function, glucose and triglycerides, temperature, blood pressure, pregnancy 
testing, contraceptive or family planning use, CD4+ T-cell count and viral load. Data collected at IPT 
initiation and follow up visits from 2011 onwards included the following variables: age at IPT start, 
weight at IPT start and during treatment, body mass index (BMI), date of IPT completion, date of IPT 
interruption, reasons for refusal of IPT uptake. All these descriptive variables in addition to monthly 





TB related procedures for those patients on TB treatment or under investigation for TB include data 
collected on diagnosis (PTB, MDR, XDR or extra pulmonary) Chest X-ray reports, sputum, smear 
microscopy, drug susceptibility testing (if applicable), ultrasound reports (if extra pulmonary TB), 
culture conversion, concomitant medication, TB treatment and phase (if applicable) start and end 
dates, treatment outcomes (in terms of success, failure, MDR or XDR TB diagnosis) and importantly 
contact tracing (if applicable) for immediate referral to local clinics. 
Patients with no TB symptoms and deemed eligible for IPT underwent screening and initiation visits 
that included ASP counselling, the importance of IPT, reasons for starting IPT, how to use INH, the 
importance of maintaining adherence to avoid development of INH resistance, discussion of possible 
side-effects, avoiding contra-indicated substances and drugs, as part of the IPT package counselling.  
A participant locator sheet was maintained by study staff that contained detailed information on the 
patients address and contact details at home and if applicable was reviewed and updated at each visit 
for being able to maintain contact with patients and physically tracking patients to bring them into the 
clinic to attended visits if necessary. The pharmacy assessed patient comprehension of the IPT 
counselling at the time of dispensing and in addition provided more motivational adherence 
counselling and advice on coping with pill burden. A counselling checklist and IPT counselling script 
was used by clinic and pharmacy staff to facilitate these counselling sessions. The candidate 
performed IPT related duties and processes as part of the pharmacy team that worked on the parent 
study. 
The following IPT related CRFs and/or source documents were completed at IPT initiation, at 
monthly follow-up visits and ad-hoc as required at interim clinic visits or reporting periods:  
• Plate #077 IPT Initiation/Follow up CRF (Appendix G) – If IPT started or not, reason for not 
starting, any change in IPT status, date and reason for change, any missed doses and reasons for 
it, side effects experienced and grading of severity, end date of IPT therapy 
• Plate #078 IPT pill count CRF (Appendix H) - Visit date; IPT treatment; Drug Type; Drugs 
returned, lost or reported as remaining at home; and any reasons for missing doses 
• Plate #76 Laboratory Results (Appendix I): AST, ALT 
• Plate #64 TB screening and risk assessment (Appendix J) 
• KZN DOH IPT monthly statistics reporting form (Appendix K) 
 
The computer package known as iDART refers to the intelligent Dispensing of ART was a very 
useful tool in maintaining accuracy and accountability of drugs and electronic patient dispensing 




drug formulary of ART drugs to enable computerised dispensing of IPT, adherence calculation, data 
collection and IPT reporting. Capabilities available on iDART are detailed in Appendix L.  
In addition, the pharmacy staff provided adherence support counselling as needed or referred cases 
identified back to clinic staff for targeted counselling. Tools to enhance adherence such as once or 
twice daily pillboxes, HART© blister packs and cell phone alarm reminders were recommended to 
patients who needed them. Patients were also trained and educated using Drug identification charts 
created by pharmacy staff to distinguish between the different ARVs drugs and INH they were taking 
for IPT, common and/or trade names, colour and shape of tablets and what the original drug 
packaging looked like. Pharmacy staff in conjunction with the multidisciplinary clinic team were 
committed to making concerted efforts to enable patients to be aware, responsible and continuously 
involved in the decision making process on their ART and IPT outcomes, adherence and overall good 
health and quality of life. 
 
2.6 Data analysis 
All TRuTH Study CRFs were Quality Controlled and data faxed into the CAPRISA database after 
validation for completeness and accuracy. The study statistician downloaded raw data collected from 
CRF completion per participant in the TRuTH study and provided an MS Excel spreadsheet to the 
candidate to perform data clean up and extraction for the secondary analysis. Any missing or 
conflicting data, trends or errors identified were verified by physical review of hardcopies of source 
documents and charts notes in the participants’ clinic file and in turn sent back to the study statistician 
for review and re-faxing into the database.  
The candidate selected the following variables (Table 8) related to IPT and patient characteristics that 
were analysed at different time points during the Truth Study: 
• Baseline demographics at TRuTH enrolment: age, BMI, Hb, viral load, gender, race, marital 
status and employment. 





Table 8: IPT and patient related variables for analysis 
Variable Variable Type Descriptive measures 
Age Quantitative (Continuous)  Frequency 
Gender Quantitative / Categorical (Nominal)  Frequency 
Marital status Quantitative / Categorical (Nominal)  Frequency 
Employment Quantitative / Categorical (Nominal)  Frequency 
Weight Quantitative  Mean with Standard Deviation or 
Median with Interquartile Range 
BMI Quantitative  Median with Interquartile Range 
CD4 Quantitative  Median with Interquartile Range 
Viral load Quantitative  Frequency 
Hb Quantitative  Mean with Standard Deviation  
ALT Quantitative  Median with Interquartile Range 
AST Quantitative  Median with Interquartile Range 
IPT completion date Quantitative  Numeric 
IPT Interruption date  Quantitative  Numeric 
Reasons for interruption  Qualitative  Frequency 
Years on ART before IPT   Quantitative  Numeric 
Adherence  Quantitative Median with Interquartile Range 
 
The candidate worked in conjunction with the statistician to perform the following statistical analysis: 
• Continuous data were summarised using means with standard deviation or medians with 
interquartile range.  
• Categorical data were summarised using percentages.  
 
Wilcoxon signed rank sum test was used to compare selected laboratory measurements before and 
after IPT initiation. The statistician calculated the TB incidence rates and follow-up duration before 
and after IPT initiation from TRuTH study enrolment to either date of TB diagnosis or one day before 
date of IPT initiation and from IPT initiation to either date of TB diagnosis or study termination date 
respectively. The mean monthly adherence to IPT was assessed by the statistician using monthly pill 
count data by comparing the number of tablets returned at the current visit with the number of tablets 
dispensed at the last clinic visit compared to the number of tablets that should have been ingested 





The formula for the mean monthly adherence quantified as a percentage included:  
Number of tablets dispensed at the last clinic visit – [Number of tablets not ingested] # x 100  
    Number of tablets dispensed at the last clinic visit 
# Where no of tablets not ingested = [number of tablets returned + number of tablets reported at 
home + number of tablets lost]  
Univariate and multivariate log-binomial regression models were used to identify predictors of IPT 
completion. To account for multiple measurements for each participant, generalised estimating 
equations (GEE) for a multivariate repeated measure logistic regression model was used to identify 
predictors associated with high IPT adherence (≥80%) over time. Previous studies have used 80-90% 
adherence threshold to describe optimal adherence to IPT (71, 85, 122). Statistical analysis was 
performed using SAS Version 9.4 (SAS Institute, Cary, North Carolina). All statistical tests were 
conducted at a 5% level of significance. The candidate used GraphPad Prism version 5.01 to create 
graphs depicting adherence and liver function test results. 
 
2.7 Ethical considerations and confidentiality 
As this is a retrospective review, no direct patient interaction occurred and thus informed consent was 
not required for this secondary analysis. However, informed consent was obtained in the parent study 
CAP005 TRuTH for the use of the clinical and demographic data. Expedited ethics approval and 
postgraduate approval for the secondary analysis was sought from the UKZN Biomedical research 
ethics committee. Ethics approvals for the parent CAPRISA 005 TRuTH Study where IPT was rolled 
out was obtained from UKZN Biomedical research ethics committee [BREC reference numbers: 
BE373/14 (secondary analysis), BF051/09 (parent study- CAP 005 TRuTH)]. Data extraction was 
conducted in such a manner that patient confidentiality was maintained at all times. Each patient was 
allocated unique participant identification number (PID) that was used documented on all case report 














3. CHAPTER THREE: MANUSCRIPT 
 
3.1 Manuscript Implementing Isoniazid Preventive Therapy in a TB-treatment 







































3.2 Discussion of the paper 
 
South Africa has the largest ART programme in the world and is also home to the largest cohort of 
patients ever initiated on IPT since the WHO recommended intervention for TB prevention was 
adopted, in country, in 2010. There is a paucity of IPT related data within TB/HIV integrated 
programmes in dual high burden settings. The paper submitted addresses IPT outcomes in an ART 
and TB treatment experienced urban population in keeping with the objectives outlined in this thesis 
with the intention to contribute to bridging the existing knowledge gap. We hypothesized that 6 
months of IPT would decrease TB incidence in a high HIV/TB burden setting amongst a treatment 
experienced cohort.  
The baseline social characteristics of patients enrolled into the TRuTH Study were presented using 
descriptive statistics. Other baseline patients’ characteristics related to IPT were collected, at least 
within 3 months closer to the time point at which IPT initiation occurred. Data on various IPT 
implementation outcomes were reported. Wilcoxon signed rank sum test was used to compare 
selected laboratory measurements before and after IPT initiation. Univariate and multivariate log-
binomial regression models were used to identify predictors of IPT completion. To account for 
multiple measurements for each participant, generalised estimating equations (GEE) for a multivariate 
repeated measure logistic regression model was used to identify predictors associated with high IPT 
adherence (≥80%) over time. The variables modelled included age, gender, Hb, CD4, number of TB 
episodes in the past and years on ART. Statistical analysis was performed using SAS Version 3.2 
(SAS Institute, Cary, North Carolina). 
Eligibility for IPT was high in this setting but uptake of IPT was moderate (61.6%). Trends for not 
accepting IPT were identified; more males refused IPT (54.7%; p<0.001) and the most commonly 
attributed reason for refusal was the inability to attend monthly clinic visits (34.6%) that were 
required for IPT. IPT exposure resulted in a non-significant decrease of 33% in the TB incidence rate 
amongst IPT users. There were 13 TB events before and 9 events after IPT exposure. Completion rate 
(86.8%) and adherence to IPT (97.6%) remained high amongst patients. Women and those with a 
higher CD4+ T-cell count tended to show better IPT adherence. Age, gender, CD4, Hb, previous TB 
episodes and years on ART were not identified as predictors IPT adherence or completion in the 
univariate or multivariate analysis. An investigation of LFT levels before, during and after IPT use 
showed no significant toxicity was sustained with 6 months IPT (AST: p=0.514; ALT: p=0.081). IPT 
was well tolerated overall and the occurrence of adverse events due to INH was minimal (3.8%). 
Six month IPT roll-out in a TB/HIV endemic setting was successful. Overall, we demonstrated that 
IPT is a safe and tolerable TB prevention intervention within ART programmes and importantly 




3.3 Master’s student contribution 
 
Student Name: Bhavna Maharaj 
Student number: 9705220 
Title of the article: Isoniazid Preventive Therapy implementation within an ART programme in 
a TB-treatment experienced cohort 
Authors: B Maharaj, XXXX, N Yende-Zuma, A Naidoo, K Naidoo 
Journal: International Journal of Tuberculosis and Lung Disease 
 
Master student’s contribution:  
1. CAPRISA 005 TB recurrence upon Treatment with HAART (TRuTH) Study-  
I served as a pharmacist on the study within the pharmacy team, including amongst others Anushka 
Naidoo (Senior Pharmacist) and XXXX (Head of Pharmacy), who dispensed IPT and ART to all the 
patients enrolled. My duties and contribution included the following: 
• Dispensed directly to patients using computerised dispensing system 
• Involved in design and implementation of IPT Adherence Support Programme (ASP) material for 
ART/IPT counsellors at the clinic. This included initial training of counsellors for IPT ASP as 
well as ongoing staff refresher training and training of new staff. We conducted second check or 
verification of IPT ASP administered to patients by counsellors, regularly provided feedback on 
IPT ASP process by telephone, at meetings or face-to-face. 
• Counselled patients with IPT adherence or compliance issues 
• Referred patients with poor adherence to IPT at follow up visits for ASP, if needed 
• Conducted physical pill counts and completed pill count plates at each monthly visit 
• Ensured accurate completion of TB symptom Checklist on patients INH script by clinical staff at 
each monthly visit 
• Verified weight based INH dosing reference ranges were adhered to and dose adjustments made if 
required, at each follow up visit 
• Provided weekly/monthly feedback on IPT statistics to the clinic team and DOH 
• Ordering and procurement of INH stock, stock management of INH stock to ensure site needs 








2. Formulation of Hypothesis 
Working in conjunction with my supervisor, XXXX, we formulated the study hypothesis, concept 
sheet and research proposal for this post graduate study which was submitted to UKZN Biomedical 
Research Ethics Committee and Postgraduate Office for expedited review to obtain ethical clearance 
and full approval to conduct the study.  
3. Study Design 
Kogieleum Naidoo was the site project director and principal investigator in the TRuTH Study. She 
was involved in initial site IPT training and guided the TB incidence analysis. Santhana Gengiah 
served as TRuTH Study co-ordinator and assisted with integrated ART/IPT clinic flow design. The 
retrospective analysis of TRuTH Study data and pharmacy IPT data was designed and conducted by 
myself under supervision of Tanuja N. Gengiah, Head of Pharmacy. 
4. Data Analysis 
I reviewed pharmacy IPT prescriptions, pharmacy computerised dispensing records and source 
documents and CRFs in patient clinic files together with an MS Excel download of the study 
electronic database provided by the statistician, Nonhlanhla Yende-Zuma. I identified errors and 
incomplete data entries as well as resolved queries generated by the statistician on the relevant CRFs. 
The update CRFs were re-faxed into the electronic database after quality control and validation with 
CAPRISA data management department. I conducted some initial analyses on the pharmacy 
computerised dispensing system, iDART, as well as data extraction from clinical chart notes and 
CRFs using MS Excel and created some of the tables and figures used in the manuscript on Graph Pad 
Prism 5. The statistician, Nonhlanhla Yende-Zuma, created and reviewed tables and figures during all 
variable tests, adherence assessments and multivariate analysis in SAS version 3.2 and confirmed all 
analyses. 
5. Write up 
I took overall responsibility for writing up and preparing the draft manuscript before submitting to all 
co-authors for review and input. All the co-authors feedback and comments were considered and 
incorporated into the revised manuscript and then sent for internal review to the CAPRISA Scientific 
Review committee (SRC). Recommendations for improvement and approval to submit were received 
from the SRC before the final version of the manuscript was submitted to the journal. Turnitin was 
used to verify originality and authenticity of the manuscript before final submission. 
I declare the above to be a true reflection of my contributions to this journal article. 















4. CHAPTER FOUR: OVERALL DISCUSSION 
 
4.1 Discussion of major findings  
TB remains the leading cause of death amongst HIV positive people around the world (123). The 
2016 WHO TB Global Report highlighted very disheartening statistics with only 9 of the 30 countries 
with the highest dual burden of TB and HIV reporting provision of TB preventive therapy (123). 
While IPT has been proven to be an effective strategy in many settings for TB prophylaxis, it is still 
an under-utilised intervention; irrespective of the clear evidence that it saves lives and offers a line of 
defence in the face of the overwhelming and rapidly increasing rates of TB transmission and re-
infection amongst HIV infected people. 
Prior to 2010, people with a past history of TB were excluded from receiving IPT since IPT was 
intended to be a primary preventive measure prior to a first episode of TB and there was not enough 
evidence to support its use in former TB patients. Moreover, ART provision and TB treatment 
services were segregated and still remain so globally, including regions in SSA. Previous reports have 
highlighted provider related barriers to IPT implementation. These include lack of knowledge of IPT, 
lack of access to policies, guidelines or adequate training which would translate to missed 
opportunities for other preventive measures including TB screening, IPT and ICF.  
We were able to demonstrate that IPT could be successfully introduced into HIV care and taken up by 
a unique cohort of patients on ART where every single patient had TB previously and was exposed to 
TB treatment. IPT was safe and well tolerated among our patients. Importantly, once patients started 
IPT they maintained high levels of adherence and the majority completed the IPT course successfully. 
Our findings add to the existing evidence of the benefit of integrated IPT with ART in this specific 
high risk group of patients where previously published data on IPT outcomes has been very limited. 
The aims for our study was to assess both the operational and clinical outcomes of IPT programme 
implementation in a high burden TB/HIV co-infection setting in a unique cohort of patients on ART 
and also previously exposed to TB disease and treatment. Each objective of this study was met as 
follows: 
4.1.1 Primary Objective 1: To assess the design and implementation of IPT roll-out within an ART 
programme 
A strategy entailing combining chronic clinic visits for ART collection with IPT collection at the 
same visit represents the ideal approach to aid successful uptake of IPT. In our study we were able to 
demonstrate effective integration of TB prevention services with HIV care. IPT provision was feasible 
in our HIV clinic, located in dual high disease burden setting, and found to be acceptable as 
demonstrated by the high uptake of IPT by patients on ART. The flow of the procedures required 




IPT adherence and 6-month course completion rates were attributed to patients being accustomed to 
taking ART and being encouraged by the staff to adopt the same adherence strategies with IPT as they 
did with ART. The current research showed that the majority of patients that were poor adopters of 
IPT due to the monthly clinic visits required for IPT collection. These patients remained at risk for 
incident TB or if they were previously exposed to TB, but now stable on ART, at higher risk for 
recurrent TB. Integrating IPT implementation into existing ART programmes provides an opportunity 
to increase retention rates, improve IPT uptake and enhance adherence to the IPT regimen 
In support of concomitantly administered IPT and ART, the THRio study demonstrated a 76% 
reduction in TB incidence after adjusting for age, past TB and immune status (32). Researchers that 
assessed the 6 month open label phase of IPT in the BOTUSA study linked the lower incident TB rate 
observed with concomitant use of ART amongst the patients enrolled in the study (48). Data from 
SSA has demonstrated that concurrent ART and IPT (31, 53, 54) or initiating ART soon after 
completing IPT (68) results in higher reductions in TB incidence compared to treating with either IPT 
or ART alone. It is important to remember that even though not statistically significant in our study, 
TB incidence was reduced among those patients that took IPT. When comparisons were made of TB 
incidence or the number of TB cases reported before and after IPT exposure, TB incidence of those 
that did not take up IPT remained the same in the study (Table 9).  
More recent findings from Tanzania also reported high acceptability of IPT integration among 
patients on ART and corresponding high rates of IPT adherence and course completion (85). A study 
conducted in the Democratic Republic of Congo in 2014 reported rates of IPT uptake at 73% and 
88.2% completion; notably patients on ART at IPT initiation were more likely to complete IPT than 
those who were not [89.2 vs. 83.3%; aOR1.54 (95%CI,1.02- 2.32)] (81). The TEMPRANO study, 
conducted in patients with a CD4+ T-cell count > 500 cell/mm3 also demonstrated 57% decrease in 
TB incidence among early ART and IPT initiates compared to those who didn’t use IPT (31). The 
effect of early ART initiation was seen at month 12 with 84% of the cohort had achieved undetectable 
viral loads & 83% remained undetectable at month 24. Overall, CD4+T-cell count remained>500 
cells/mm3 for 51% of the time. The cumulative probability of death or severe HIV-related illness was 
5.7% in the early arm and 8.8% in the deferred arm. Thus the main finding from TEMPRANO 
highlighted that early ART integrated with IPT lowered severe HIV-related illness by 44% and all-
cause mortality by 35%. The risk of death also decreased by 35% compared to the deferred group.  
Looking at the benefits derived from IPT implementation in the studies described above, we can see 
that our study re-affirmed that the implementation of IPT can reduce incident TB among patients on 
ART previously treated for TB, although this was not statistically significant. Adopting IPT as part of 
a TB prevention package with ART enhanced the level of clinical care provided and improved 




Over and above the beneficial impact that IPT implementation had on patient health, the clinical skills 
of the healthcare providers at our clinic were improved. Having the capacity to provide clinical care 
for both HIV and IPT resulted in a more comprehensive healthcare service to the HIV infected 
patient. In addition, service integration provided an opportunity to conduct intensified case finding of 
TB and provide IPT services for TB prevention within an already strong, established HIV setting with 
many support structures in place to act as an adjunct to the implementation of TB prevention efforts. 
The roll out of IPT began efficiently with minimal logistic or operational issues experienced since it 
was built upon an existing HIV services in our facility. There was little to no need for extensive 
resources to be laid out so minimum effort but maximum output of IPT programme implementation 
benefit was achieved. 
The provision of ART, TB and IPT services as part of an integrated package is integral to the success 
of TB prevention campaigns. The ultimate goal of national health programmes in SA and other high 
burden countries around the world should be to aspire to attain zero TB transmission and re-infection 
rates, with IPT and other TB preventive measures as part of the arsenal. Much work is still needed to 
“stop TB in our lifetime” (Stop TB partnership World TB Day 2012/2013 slogan: Stop TB in my 
lifetime). 
 
4.1.2 Primary Objective 2: To report on the outcomes of the IPT roll-out 
The current study was able to explore TB incidence and other clinical outcomes of IPT as well as 
areas of IPT implementation that require strengthening and modification. This objective was achieved 
as follows: 
Our study showed good IPT uptake, high adherence and completion rates with minimal course 
interruption for IPT related adverse events. These findings suggest that 6 months of IPT was safe, 
effective and well tolerated amongst stable HIV infected patients on ART who had all been treated for 
TB previously.  
IPT uptake 
We found the overall IPT uptake in our study (61.6%) to be good but lower than expected in this 
context. Previous reports of low uptake and course completion were due to poor knowledge of IPT 
and poor patient understanding of the concept of TB prevention (93), whilst others reported being 
motivated by fear of TB and its related complication or being knowledgeable of the potential benefit 
of IPT that contributed to high IPT completion rates (75). Similarly, our patients were kept informed 
through education, awareness campaigns and information sharing sessions via group education 




pharmacy staff, nurses and clinicians) on aspects including, but not limited to, IPT importance, 
management of side effects and how to cope with co-infection. 
 
Taking into consideration the support given knowledge and experience our patients have gained by 
being on ART for years and having managed either one or more courses of TB treatment, we had 
anticipated a much higher percentage than the 61.6% of the cohort accepting the benefits of TB 
prevention. With this history in mind, the candidate looked further into patients’ reasons for refusal of 
IPT. Socioeconomic related factors, most-likely may have contributed to the lower than the 75-80% 
uptake expected. In our study the requirements for monthly IPT follow up visits was the commonest 
reason for IPT refusal (34.6%), probably due to high unemployment rates and the associated costs of 
frequent clinic attendance. This reasoning provides a partial explanation, as we also noted that more 
males (54%) refused IPT, which was a significant finding observed in this study and discussed further 
below.  
Various studies have reported on themes related to stigma and poor socio-economic status, amongst 
others, which have had a detrimental effect on IPT use (86, 118, 120). Norms of society dictate that 
men are usually the breadwinners in the household (124). It can be safely inferred that the added 
burden of loss of earnings with having to miss days at work every month in order to attend clinic, or 
being afraid to request time off from work as a result of non-disclosure contributed to IPT refusal. 
Stigma associated with HIV and TB still exists in communities. A meta-analyses shows highly 
variable IPT uptake in SSA ranging from 13-95%(45). Even more concerning were the high rates of 
loss-to-follow-up reported with associated poor IPT course completion and outcomes (118, 125). In 
comparison, the majority of patients in our study that started IPT eventually completed the course, 
contributing to the high completion rate observed (86.8%). Strategies aimed at improving IPT uptake 
and retention need to optimise IPT access, reduce clinic attendance, find innovative and convenient 
ways to enhance adherence to IPT and ART and symptom monitoring for new TB infection. 
Contribution of background TB to IPT ineligibility  
It was observed amongst ineligible patients in our study that presumptive TB, confirmed TB and/or 
drug resistant (DR) TB accounted for almost a third of patients not being considered for IPT. Once 
patients initiated IPT, continuity of the course was monitored and reasons for any IPT interruptions 
was documented. One of the main reasons cited for IPT interruptions was presumptive TB. However, 
only two of the 26 interruptions were eventually diagnosed with TB. Given the high TB burden in the 
study setting, the index of suspicion for incident TB by HCWs was understandably raised, resulting in 
frequent IPT treatment interruptions for TB investigation. A study that conducted an operational 
assessment of IPT in Uganda reported that of those non-eligible for IPT, 79% were due to active or 
presumptive TB (125). Findings from Botswana looking at reasons for non-eligibility for IPT 




not necessarily indicative of TB, and the subsequent second phase of IPT screening identified 35% 
not eligible due to chest radiograph indicative of active or presumptive TB (48). More efficient point 
of care diagnostics for TB such as GeneXpert may play a role in reducing IPT course interruptions, 
and re-entry into the IPT programme.  
Gender disparity in IPT uptake 
Gender differences in IPT uptake are evident with more females taking up the TB prevention 
intervention than males consistent with other studies: a study in South Africa (19) in 2009 reported 
80% of IPT users were female while researchers in Ethiopia observed uptake of IPT of 61.4 – 69.6% 
in women (13, 24). Another study observed that more men were reported as non-adherent and lost-to-
follow-up (aOR: 2.24, 95%CI, 1.24-4.04) and (aOR: 3.08; 95%CI, 1.50-6.33) respectively. A study in 
South Africa reported men were more likely to get TB (IRR 1.46; CI 1.09-1.94). It can be inferred 
from these findings that targeting males for enhanced supportive TB preventive counselling would be 
a valuable intervention to consider in improving IPT uptake in men. 
Effect of IPT on TB incidence 
For those patients in the TRuTH study that did not initiate IPT, the TB incidence rate remained more 
or less the same for the duration of the study. Due to the small numbers and reduced follow-up, we 
noted a decrease in TB incidence after 6-months of IPT exposure that was not statistically significant, 
among patients with previous TB on ART. We demonstrated that IPT works in this important group 
of individuals at high risk of both recurrent and drug resistant TB; however, a one third reduction in 
incidence is not acceptable considering the high background TB transmission rates and the synergistic 
effect of ART in this population.  
Additional data on TB incidence data, one of the main objectives of the parent TRuTH study will 
appear in the publication of the outcomes of the parent study. For the purposes of this thesis, there 
were limited permissions granted with regards the extent to which TB incidence data could be 
reported in the IPT manuscript prior to the TRuTH study manuscript being published. Hence we 
looked at TB incidence only among those that took IPT. For the purposes of the thesis only, 
permission was granted from the parent study PI to discuss TB incidence among the entire cohort 
including those that were not exposed to IPT. These findings are presented in table 9, specifically for 

















Initiated on IPT 
Before IPT After IPT 
No. of TB cases 38 25 13 9 
Person-years 906.1 578.6 328.1 337.3 
TB incidence 4.2 4.3 4.0 2.7 
95% CI 3.0 - 5.8 2.8-6.4 2.1-6.8 1.2 - 5.1 
 
While TB incidence remain unchanged in those patients not exposed to IPT, there was a statistically 
non-significant decrease in TB incidence among those patient ever initiated on IPT compared to those 
who did not. 
Implementing IPT among patients with a past history of TB and TB treatment exposure 
Prior to 2010, patients previously exposed to TB treatment were considered ineligible for IPT. 
However, subsequent studies amongst mine workers in South Africa in the absence of ART provision 
have demonstrated an increased risk of recurrent TB for patients who have experienced previous 
episodes of TB (36, 69) and that IPT was effective, (RR 0.19; 95% CI: 0.04-0.42) and (IRR 0.62; 95% 
CI: 0.43-0.89) respectively. In settings with routine ART provision such as Brazil, the TB risk still 
remained (RR=1.37; 95% CI 1.04-1.80) (32). The similar risks would apply in our cohort where all 
100 % had previously been treated for TB. The non-significant reduction in TB could also be 
interpreted as an indication that in this type of high risk cohort other interventions need to be put in 
place in conjunction with IPT implementation to enhance the protective effect. More research should 
be done on longer duration of IPT, combination preventive therapy with additional drugs or other re-
purposed interventions specifically for those patients receiving preventive therapy secondary to TB 
treatment. 
IPT associated resistance to INH 
Two cases of TB were diagnosed while the affected patients were on their fifth month of IPT. Both 
cases stopped IPT and went on to be successfully treated for drug-susceptible TB. As discussed 
previously, fear of INH resistance has been reported as a major barrier to IPT implementation in the 
past yet existing evidence has shown that IPT has not significantly raised INH resistance (34, 35). It is 
important to continue track the impact of IPT on INH resistance. More research is needed on this 
particular aspect. 




Current WHO guidance, supported by other research,(34, 76, 126) recommend that IPT be provided 
for up to 36 months in a high TB burden setting (38). Several studies have shown that IPT was more 
effective if the duration of IPT went beyond six months. In South Africa, a study conducted in Soweto 
using 12 months IPT either simultaneously or after ART reported TB incidence of 2.3 per 100 p-y 
compared to 3.6 per 100 p-y using placebo (126) .The BOTUSA Study reported a 43% TB reduction 
with 36 months of IPT compared to six months IPT provision in Botswana; the strongest impact 
occurring amongst TST positive individuals who demonstrated 74% TB reduction. Another South 
African study demonstrated that continuous IPT for 6 years resulted in 58% reduction in TB risk and 
death compared to 6 months IPT (76). Interestingly, the TEMPRANO trial demonstrated that 6 
months of IPT initiated with immediate ART reduced the risk of severe HIV-related disease (44%) 
and all-cause mortality (35%) significantly (31). It stands to reason that the co-treatment with ART 
contributes to the benefits seen and should be considered along with the duration of IPT exposure. 
The above pinpoints a few reasons for the non-significant IPT effect seen in our cohort: small number 
of patients, shortened follow up time and insufficient duration of IPT. More research needs to be done 
to determine if patients with a past history of TB on ART would benefit more from extended IPT 
regimens rather than 6 months IPT. 
Adherence to IPT 
Adherence to IPT has been described previously using IPT completion rates, medication adherence 
(pill count) or prescription refills. Our IPT completion and adherence rates were similar to reports 
from other African studies with findings ranging from 78- 98.9 %.(31, 34, 48, 75, 81, 84, 85). The 
BOTUSA study measured adherence at Month 1, 3 and 6 where 91% of the cohort maintained > 80% 
adherence indicated by refill rate; notably 78% maintained > 80% adherence over 36 months of IPT 
use (34, 48). The TEMPRANO study showed 6-month completion rates of 94% in early IPT use and 
93% amongst deferred IPT users. In our study we were able to report adherence by pill count as well 
as IPT course completion rate. We noted an IPT course completion rate of 86.8% similar to reports 
from other African studies: 87% in Tanzania (75) and 88.2 % in Kinshasa (81) respectively. Our 
finding of 97.6% adherence measured by pill counts was higher than the 89.5% self-reported 
adherence in Ethiopia (122) but slightly lower than a Tanzanian study that reported 98.9% (85) . High 
adherence in the current study may be attributed to the well-resourced clinical research setting, the 
structured adherence support programme, the patient being on ART and needing to come in to collect 
treatment. In addition, at the IPT screening visit patients who felt that they could not adhere to 
treatment or were deemed by the HCW as potentially non-adherent would have been excluded from 
the IPT programme after mutual agreement between the patient and HCW.  
There is strong evidence for combining ART use with IPT to significantly improve adherence to IPT 
(34, 48, 85, 122). While some studies reported predictors of IPT completion and adherence such as 




considered themselves to be at low risk for TB or did not recognise the benefits of IPT (127). We did 
not measure all these variables in our study. However, we noted a trend towards females being more 
adherent by pill count, although this finding was not statistically significant. A study conducted in 
2011 similarly reported that men had increased odds of lost-to-follow up and non-adherence to IPT 
than women (117).Some of the more recent studies have raised the threshold of IPT adherence to 90% 
(previously 80%) (76, 85). Since concurrent use of ART and IPT is associated with enhanced 
adherence to IPT, we support raising the benchmark measurement of IPT adherence to 90%. This 
level would also not have any effect on our reported adherence to IPT in this study, as the average and 
median scores per participant as well as the overall median where all far above 90%.  
Adverse effects related to IPT 
The effect of IPT on liver toxicity and the return to normal liver function post IPT cessation was 
similar to findings amongst patients taking nine months of INH where the majority of the hepatic 
dysfunction cases resolved after IPT completion and the remaining IPT users noted an improvement 
to less than 3 times the upper limit of normal (88). There was a significant association between 
baseline liver function abnormality prior to IPT initiation and abnormal liver enzymes during IPT. 
The same study (88) also noted that liver enzyme abnormalities peaked at a median of three months 
after IPT initiation, also seen in the BOTUSA study that reported a prevalence of 1.1% hepatoxicity 
amongst the 26% of the cohort that received six months of IPT and ART (87). 
There was also a similar prevalence of grade 2 and 3 liver toxicity events compared to the 6 month 
open label phase of the BOTUSA study (87). IPT interruptions due to toxicity in our study was 
minimal, side effects were reported in 3.8% of the cohort that were within the range of previous 
reports, usually ranging from 0.5% - 4% (31, 48, 126, 128). There were similarities identified between 
the side effects experienced by the patients in our cohort and other findings from SSA in terms of 
nature, severity and frequency the symptom. The most common side effect reported in our study that 
resulted in IPT being stopped was rash and is in keeping with reports from other studies (48, 69, 128). 
Some studies reported more cases of hepatitis and grade 2 or 3 LFT abnormalities, especially if the 
duration of IPT was longer than 6 months (126). Other studies reported pruritus, psychiatric 
symptoms, and other side effects that were not observed/reported in our patients (31).  
Overall, we were able to successfully integrate IPT visits with existing clinic ART visits resulting in a 
high IPT completion rates, further underscoring the efficiencies of IPT/ART programme integration, 
and reported benefit beyond reduction in TB incidence (32, 68). It is imperative that we disseminate 
such findings to hasten IPT rollout in other countries that have yet to adopt this intervention. Foremost 
should be the outcome of IPT of any duration used in conjunction with TB prevention strategies 





4.1.3 Primary Objective 3: To describe the pharmacist’s role in a multi-disciplinary approach to 
IPT implementation and roll-out 
 
Community screening 
Community/ retail pharmacists are relatively accessible HCWs (129) and are often the first point of 
contact for sick people (130, 131) and so are well placed to be able to identify and refer symptomatic 
patients with presumptive TB for further investigation, as well as household contacts of TB cases for 
IPT screening. Therefore, pharmacists and trained pharmacy staff could potentially play a dual role in 
assisting with detection of TB symptoms as well as promoting TB prevention through referrals of 
those who may benefit (131-133).  
Monitoring IPT and TB symptom screening 
Pharmacists would be an efficient and strategic cadre of HCW to monitor patients receiving IPT on an 
ongoing basis and continue to identify those displaying symptoms suggestive of presumptive TB or 
INH toxicity. In that way further investigations of side effects, diagnostic tests, intensified case 
finding and/or TB treatment initiation can be fast tracked. The standard dispensing roles would also 
apply to the operational aspects of the pharmacist activities within an IPT programme viz. 
procurement of INH, performing pill counts and adherence assessment. The pharmacist, in a 
combined role with other HCW, would ensure optimum use of INH for IPT by verifying that the 
correct dose was prescribed in accordance with the correct weight range and offer a shared role to 
decongest health care service with other members of the clinical team. In our study, the pharmacy 
staff reviewed whether weight and dose verification had been conducted by the nurses and clinicians 
and assessed the TB symptom screen outcomes as part of routine procedures during the clinic visits 
for each patient.  
Data collection and reporting including tracking and retention efforts 
As part of the multidisciplinary team the pharmacist and pharmacy staff contributed to tracking and 
retention of patients. The pharmacist played an advisory role by using auto generated computerised 
dispensing reports describing IPT initiations, missed IPT visit reports, IPT interruptions and IPT 
course completions. This data collection and reporting role also extended to reporting IPT programme 
statistic to the SA DOH.  
Role in multidisciplinary team: dispensing, training, education, IPT outcome monitoring and 
evaluation  
As part of ongoing capacity building the pharmacy team was also tasked with training of new staff 
(pharmacy staff, counsellors, nurses) as well as provide refresher training at regular intervals on IPT 
provision. Together with other members of the team, patient counselling and education (134) became 
a shared role and responsibility in addition to helping patients cope with HIV/TB co-infection in the 




overcoming barriers to medication adherence by providing tools such as medication diaries, pillboxes 
or helping patients to set up alarm reminders as prompts to take medication timeously and correctly 
(135).  
Supply chain management 
The pharmacy staff ensured that INH was timeously procured and accessible for all patients on IPT 
for the duration of their course. We were able to procure sufficient stock through the private sector. 
This is not always the case in the public sector with limited resources and so INH drug shortages or 
stock outs is a real operational challenge faced by many HCW and subsequently patients. Some 
studies have described how stock outs negatively impacted on IPT implementation and provision of 
INH (19). In Ethiopia 11 % of patients were reported to be non-adherent to IPT due to drug stock outs 
(84). Within SA, INH stock outs have also recently been cited as a major hindrance to IPT where 86% 
of patients who did not complete IPT were as a result of INH being out of stock (136). While not all 
clinics or health facilities have a pharmacist on site, ensuring adequate and unbroken supplies of drugs 
required for IPT is a critical role under the scope of practice of a pharmacist that should not be 
neglected. 
 
Overall, the pharmacist was able to contribute to staff and patient education and training through 
development of learning materials, tools and counselling guides. Power point slide presentations were 
created for clinic staff re-fresher training on IPT provision and INH side effects in addition to 
counselling tools and quick checklists for staff to use during patient education sessions. The 
operational experience gained from IPT implementation in the TRuTH study has helped to prepare for 
TB prevention interventions in other projects. For another TB study currently running at site, the 
Improving Retreatment Success (IMPRESS) study, patients on IPT are scheduled for clinic follow-up 
visits every 2 months and telephonic monitoring on alternate months using a telephone counselling 
guide developed by the pharmacist (Appendix M); in addition, IPT related data is captured on revised 
IPT CRFs, the development of which the pharmacist contributed to significantly as part of the 
multidisciplinary clinical team.  
There has been very little data published on the role of the pharmacist in the provision of TB care in 
the form of treatment or prevention (137-141). Findings from a clinic for HCWs with LTBI and on 
IPT run by a pharmacist in the United States in the early to mid-1990’s, demonstrated how the 
pharmacist was able to provide face-face or telephonic follow-up to dispense INH monthly, assess the 
overall status of HCWs as well as monitor and manage adverse effects (141). IPT outcomes showed a 
high completion rate (93%) amongst those HCWs ever initiated on IPT, with no incident TB cases 
reported (141). More recently researchers have identified the pharmacists’ role in TB related care 




private sector as well as professional regulation. This can be also easily applied as TB prevention 
strategies for the family and household contacts of those patients identified with TB. TB treatment 
and prevention go hand in hand and should not be handled in isolation from each other.  
 
4.2 Study limitations 
There were several study limitations. The small sample size, in this secondary analysis undermined our 
ability to show a statistically significant impact of IPT in preventing new cases of TB in patients who 
have had TB previously. The CAP 005 TRUTH study and this IPT sub-analyses were not powered to 
detect any significant differences in TB incidence among those initiated on IPT and those not initiated 
on IPT. A post-hoc assessment confirmed that the current study sample size of (n=212) participants was 
insufficiently powered (22%) to detect a significant difference in TB incidence before and after 
exposure to IPT. 
Additionally, our model of well-resourced IPT implementation may not be generalizable to other 
settings given the resources directed to regularly timed TB symptom screening, routine laboratory 
investigations and chest radiographs aimed at evaluating incident TB as well as the multi-disciplinary 
healthcare team utilised in the parent study. This may have led to over -reporting of suspected TB and 
subsequent non-eligibility for IPT or IPT interruptions. Increased personnel and infrastructural 
resources enabled rapid confirmation or exclusion of incident TB and efficient identification of patients 
eligible for IPT. Well-resourced clinical trial settings create a strict monitoring environment that 
encouraged focused and targeted attention on patient adherence to treatment, study visits retention and 
clinical outcomes. This may have contributed to higher IPT adherence and completion rates reported in 
the study. We also did not measure qualitative factors that may have had an impact on IPT uptake such 
as patients’ perception of TB risk, disclosure of HIV status, understanding the importance of IPT for 
TB prevention, level of education or economic status at the time of IPT eligibility assessment. 
 
4.3 Recommendations for clinical practice 
The following recommendations regarding operational considerations, clinical outcomes and the role 
of the pharmacist in IPT programmes are put forward:  
• Scale up efforts for HIV/TB/IPT service integration, previously reported in 2012 to be at 59% 
(99). There is a need to re-frame integration expectations to emphasize that the principle of one 
clinical consultation to cover all chronic requirements should be adopted, not the current system 
in place at some facilities at the moment where patients are seen “under one roof” but still have 
separate consults and follow multiple queues resulting in a prolonged clinic visits and treatment 




• Test and treat campaigns that have been launched by the SA DOH in September 2016 
recommends immediate ART initiation in all HIV infected patients. Opportunities to promote IPT 
uptake should also be incorporated as part of the package of benefits with early ART and IPT 
initiation.  
• Adopt separate strategies for IPT management based on duration of ART (treatment naïve or 
experienced at time of IPT initiation) and tailor IPT adherence counselling support accordingly. 
Treatment naive patients may need more frequent contact for monitoring both IPT and ART use 
compared to experienced patients stable on ART.  
• Restructuring of current DOH recommendation for implementing long term IPT -for TST positive 
patients on ART provision of a 36 month IPT course includes monthly follow up for first 6 
months followed by quarterly visits (142). Based on our experience derived from IPT roll-out, this 
schedule may hinder IPT uptake due to frequent clinic visits required. We would suggest a visit 1 
month after IPT initiation for safety evaluations and then move to quarterly visits with telephonic 
based follow up in between to maintain contact, conduct TB symptom screening and promote 
retention in care  
• Surveillance for incident TB by conducting TB symptom screening routinely in between physical 
clinic consultations 
• Standardised dosing of INH as 300mg daily and not weight based in order to align with current 
WHO guidelines (38). This would simplify the dispensing process, facilitate ease of use for 
patient, decrease pill burden, and avoid dosing errors. It would also be a step closer to merging 
IPT and ART provision within the newly launched Centralised Chronic Medicines Dispensing 
and Distribution (CCMDD) system, implemented in April 2016 in 11 districts around SA.  
• Provide IPT carrier cards similar to those used for TB treatment monitoring so that patients on 
extended IPT (12 and 36 months) can be monitored for IPT course duration, IPT history and 
treatment interruptions. 
• Prioritise those with a past history of TB and males for targeted counselling on IPT benefits in 
order to promote uptake 
• Revise pharmacy undergraduate curriculum to incorporate public health and 
pharmacoepidemiology courses, including IPT and TB prevention concepts of public health, into 
their curriculum and equip pharmacists as public health professionals (143)  
• Revise the role of the pharmacist within existing TB care and control policies between WHO and 
the International Pharmaceutical Federation, (FIP) to include IPT as a key component within the 
TB care continuum (144). 
• Review and revise models used for nurse-initiated management of ART (NIMART) training to 




• DOH and other related researchers (e.g. NICD) to make data more widely circulated, accessible 
and available on INH resistance patterns to keep service providers informed and assess the 
ongoing impact of IPT on INH resistance, if any. This can be achieved by commissioning the SA 
TB Drug Resistance Survey Report (83) to be conducted more frequently and disseminate the 
findings on a larger scale. One of the recommendations in the survey is that further research, such 
as risk benefit assessments be conducted, in order to determine if IPT is driving INH resistance 
and assess the continued effectiveness of IPT as INH resistance increases.  
• Promote the use of point-of-care (POC) diagnostics to rule out TB and thereby hasten the process 
of initiation onto IPT, reduce course interruptions once initiated, and ensure re-entry onto IPT and 
course completion. With the use of GeneXpert® for POC diagnosis of TB, the risk for false 
positives is a concern. Some researchers have identified the potential risk of GeneXpert false 
positivity in re-treatment TB cases to be 1 in 7 (145). GeneXpert may still play a valuable role in 
the IPT setting as opposed to none, until other point-of-care diagnostics with higher specificity for 
re-treatment TB become available. Another POC diagnostic developed by Yoon et al. has 
potential to be used to confirm IPT eligibility via C-reactive protein testing (146). 
• Innovative use of available technology over and above point-of-care diagnostics, such as mobile 
based technology, has the potential to play a crucial role in enhancing the delivery of IPT care to 
patients. Some possibilities include use of short messaging service (SMS): sending out 
motivational text messages about the benefits of taking and completing IPT, tracking and 
retention related messages for clinic appointment reminders, prompts to those who defaulted visit 
and general broadcast messages about TB prevention 
• Stock visibility system (SVS) - mobile technology based stock management system, with 
automated alerts and SMS notifications for drugs low in stock. This can be used to prevent any 
course interruptions or non-adherence to IPT due to INH stock out. 
• Promote the use of computerised dispensing systems for improved accuracy and monitoring of 
drug dispensing processes such as by improving access and availability of Rx solutions system 
being rolled out in the public sector.  
 
4.4 Recommendations for future research  
 
Recommendations for future research include: 
• Determine the impact of extended IPT duration in TB treatment experienced cohorts 
• Identify, assess and report on factors that may predict IPT refusal and aim targeted interventions 




• Design and implement innovative ways of using mobile technology to improve IPT uptake, 
enhance long term IPT adherence and continuous ongoing screening for TB and adverse effects 
with long term INH use during IPT  
o SATIETY (Self-Assessment Tool for IPT Extended therapY) is a mobile application I 
designed as a self-assessment tool for TB screening (Appendix N). This was 
conceptualised for a grant funding opportunity where it was proposed for use as a mobile 
technology based programme to enable patients on IPT to conduct self-assessed TB 
symptom screening in between clinic follow ups. The initial grant application was not 
successful but I plan to pursue this endeavour (see Appendix O for NIH R21 grant 
application review committee feedback). Some baseline data has been collected on 
cellphone infiltration and capabilities amongst TB and TB/HIV co-infected patients in the 
CAPRISA 011 IMPRESS study which would help facilitate further development in this 
project.  
o A poster presented at the TB 2016 pre-conference during AIDS 2016 on TB screening 
and referral using technology in India private sector (131) showed the potential of a 
public-private partnership linking into the national Indian government digital TB 
monitoring system known as Nikshay to scale up TB treatment; similarly there is 
potential for IPT as TB prevention to be referred into this system and monitored. More 
research targeted at IPT could be an investigation into the feasibility of tracking IPT 
initiates electronically on national TB prevention programmes. 
o ENhance Initiation and Retention in Isoniazid Preventive Therapy (IPT) Care for HIV 
Study (ENRICH Study) is a cluster randomised trial in progress at 10 HIV clinics in 
Ethiopia with behavioural combination interventions (including real time adherence 
monitoring in the form of IVR on mobile phones) vs standard of care. This type of 
intervention shows promise and should be investigated further in the South African 
context, with SA having the largest HIV and IPT programmes in the world. 
• Conduct IPT modelling research similar to the examples listed below to describe clinical 
outcomes further in former TB patients who received IPT. Such models could shed more light on 
the optimal way to approach TB prevention in this high risk population and whether long term 
protective benefits will be sustainable.  
o Tom Sumner et al. – post treatment effect of IPT on TB incidence: ART makes IPT effect 
more durable in low burden settings, but not in high burden settings where the protection 
is limited due to high transmission and re-infection rates (62) 
o Houben et al. demonstrate the ability of IPT to cure latent TB (147) 
• Investigate other TB preventive drug regimens. Some selected studies/drug regimens that are 




o CORTIS-01: weekly RPT/INH for 3 months in HIV negative people  
o ACTG 5279: daily RPT/INH for 1 month in HIV positive people 
Special emphasis should be placed on patients with prior TB and TB treatment exposure 
especially in high TB burden and dual HIV/TB burden settings to be included in above 
suggested studies; a history of prior TB should not be selected as criteria for exclusion from 
studies 
• Preventive therapy for MDR TB contacts. To date, there is no recommendation or policy in place 
in SA or globally for preventing TB amongst household contact of MDR/XDR TB patients. What 
are effective treatment regimens for household contacts of patients being treated for MDR- TB? 
Studies underway or proposed: 
o Levofloxacin 6 months [TST+ adults, Vietnam, V-QUIN study]; [any HIV and TST 
status children <5 years old, South Africa, TB-CHAMP study] 
o  Delaminid 6 months [HIV positive and any age, ACTG IMPAACT networks, PHOENIx 
study]- Preventive therapy for MDR TB in children, adolescents and adult household 
contacts (pregnant women) 
Too little to none has been accomplished in this field. More studies, more investigational drugs 
re-purposed for TB prevention as well as other interventions need to be more broadly 
investigated. 
• Promote awareness within the pharmacy fraternity and send out a call for more research on the 
role of the pharmacist in TB prevention 
 
 
4.5 Concluding statements  
 
In conclusion, the statements below summarise the findings and support the use of IPT in HIV 
infected patients on ART with TB treatment experience: 
• IPT is an effective TB prevention intervention within ART programmes.  
• Six month IPT course can be successfully rolled out in a TB endemic setting with good uptake of 
IPT, where minimal course interruptions or side effects were reported and majority of the cohort 
completed the IPT course.  





Current evidence still strongly maintains that IPT does not increase resistance to INH; the longer the 
duration of IPT the better the protection; independent ART or IPT use in HIV infected people does 
offer protection against TB. However, integrated ART and IPT provision is most effective in reducing 
the risk of mortality. TB continues to undermine the success of ART programmes in SSA, and our 
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L. iDART capabilities 
The computerised dispensing system iDART include: general admin [add new users, drugs, stock 
locations, load doctors details and option to update details in these categories]; patient admin [add 
new patients, create new or update prescription, generate patient specific reports such as adherence 
history]; dispensing [add stock, dispense stock, do stock takes and generate reports] and reports.   
  






The main functions of the iDART system that were utilized for IPT and ART provision: 
• A Pharmacy stock location for ARVs and INH from where stock was selected for dispensing and 
stock balances could be reviewed. 
• An IPT Clinic was created to record all participants initiated onto IPT and facilitated dispensing 
of INH to participants by recording details of dispensing process such as pills returned from 
previous visit, quantity and batch number of drug dispensed at current visit. 
• Product labels: labels generated displayed the amount of study drug that was re supplied and/or 
re-issued, the next appointment date, the participant number, participant initials, etc.  
• Reports generated to assist with patient tracking and retention, IPT course outcomes in terms of 
start and end dates, patient adherence reports, electronic pill counts, missed visits, patients 
expected on a day, monthly drug usage, daily dispensing totals, packages leaving pharmacy for 
the day, monthly issues and receipts, stock take, clinic indicators report, PEPFAR reports, etc. 
This system had the advantage of also assisting the pharmacy staff in picking up any 
discrepancies as well as identifying errors that could be rectified quickly within a short space of 
time. Dispensing time was shortened and errors minimised as this system served as a double 







Dispensing on iDART (148) 
1. Dispensing directly to patients is selected 
2. The prescription issue number and the no of months’ supply to dispense.  
3. Date Packed – this is the date that the dispensing took place.  
4. Next Appointment. This is based on the Date Packed as well as the months’ supply or can be 
adjusted manually.  
5. The pill count feature may be used to check the adherence then enter the amount of pills returned 
from the previous package dispensed. Green > 94%; Yellow 90%-94%; Red < 90% 
6. Drugs to Dispense in This Package table- each row represents a prescribed drug. It shows the 
Drug Name and the Dosage (based on the prescription you've already captured). 
7. The Dispense column tells you how many units of the drug will be dispensed. To change the 
quantity, click in the row and the Batch Information Screen loads. On this screen, you can change 
the quantities, the batch from which the medication was given as well as the amount of labels to 
print. 
8. A column to inform the user how much stock is left of the drug (Packs in Stock). You cannot 
change this value here; it is shown more for reference purposes so that you can see when you're 




9. If the amount of pills dispensed is more than the amount in the bottle, then a 2nd label is printed 
to stick onto the second bottle. That column tells you how many labels will be printed (Labels). 
You can change this if you want by clicking in this column. 
10. The In Hand column tells the user how much medication the patient will have in their hands when 
they leave the pharmacy. If you used the pill count feature, this will be the amount they came 
back with, plus the amount you have dispensed. 
11. Note that if your patients keep their left over pills from the previous visit, then the value in the In 
Hand column should automatically be the combined amount. If you have to change it every time, 
then you must speak to an iDART technician to change your settings. 





M. IPT telephonic checklist (IMPRESS Study checklist) 





Contact No:                   (Confirm contact number and update locator if changed) 
 
Date contact made:  
 
INH SIDE EFFECTS YES NO N/A 
Nausea       
Vomiting       
Jaundice       
Urine colour - dark yellow to brown       
chest pain (right upper quadrant abdominal pain)       
convulsions       
rash       
psychosis       
peripheral neuropathy       
TB SYMPTOM SCREENING YES NO N/A 
Do you have any of the following:       
drenching night sweats or sweating unusually at night       
loss of weight       
coughing for XX (2 weeks or more)       
coughed blood       
fever or chills lasting 3 or more days       
chest pains or difficulty breathing       
swelling in the neck and/or armpits       
TB RISK  YES NO N/A 
Any TB contact since the last visit/staff contact?       
Action required (If yes to any of the questions above): YES NO N/A 
refer for clinical review of responses      
book clinic consult for further investigation      


































O. Extract from National Institutes of Health R21 grant application review committee 
feedback for SATIETY USSD project: outcome – not funded 
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